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 ABSTRACT 
 
TITLE OF THE ABSTRACT: Protein p16 immunohistochemical expression in 
premalignant and malignant lesions in cervical histopathology specimens and its clinical 
outcome.  
DEPARTMENT : Pathology 
NAME OF THE CANDIDATE : Nivedita Suresh 
DEGREE AND SUBJECT : MD. Pathology  
NAME OF THE GUIDE : DR. Ramani Manoj Kumar. 
OBJECTIVES:  
a. To evaluate the diagnostic utility of p16 to differentiate between the 
premalignant and malignant squamous and glandular lesions of cervix. 
b. To assess the utility of p16 to distinguish between benign and dysplastic 
lesions of cervix. 
c. To assess the clinical impact of p16 expression on the disease outcome. 
d. To assess the performance of cytology as a screening tool compared to 
histology. 
METHODS:  120 cervical biopsies (15 cases each of CIN 1, 2, 3 and squamous cell 
carcinoma, 22 cases of adenocarcinoma and 38 reactive cases) were studied and p16 
immunohistochemistry were performed. Score out of 8 was given based on intensity 
and proportion of p16 expression. Corresponding cytological diagnoses were also 
evaluated. 
 
RESULTS:  Sensitivity of p16 in CIN 1, 2, 3, squamous cell carcinoma, adenocarcinoma 
were found to be 73.7%, 93.3%, 93.3%, 100% and 95.4% respectively. Specificity of p16 
in cervical squamous and glandular lesions was 85.7 % and 80 % respectively. p16 over 
expression also correlated with stage of tumour, lymph node metastasis, local and 
distant metastasis. Intensity of expression correlated better with lesion severity than 
proportion. It did not correlate with grade of the tumour. 15.7 % of reactive epithelium 
showed patchy weak cytoplasmic positivity for p16. 
  Cytology had sensitivity of   35.7 %, 69.2% and 50% for low grade lesions, high grade 
lesions and glandular lesions respectively. 
 The time taken for a dysplastic lesion to progress into a higher grade lesion was 16 
months. Among the morphological parameters used to diagnose cervical dysplasia, 
mitotic count was found to be the only parameter which showed statistically significant 
difference among the subtypes.  Koilocytosis was significantly associated with CIN 1 and 
CIN 2 but not with CIN 3.  All the cases of koilocytosis were negative for p16. The most 
common presenting symptom was vaginal discharge in CINs and cervical growth in 
carcinoma. 15.8 % of women with CIN 1 were referred for biopsy due to abnormality in 
Pap smear. 
CONCLUSION:  p16 is a reliable marker to detect cervical dysplastic lesions. It can 
differentiate benign mimics from dysplastic lesions. Over expression of p16 is 
associated with higher stage of tumour, nodal and distant metastasis. Pap smear test 
alone has a low sensitivity for low grade lesions.  
Key words: p16, CIN, Squamous cell carcinoma, Adenocarcinoma, glandular lesions, 
Pap smear, cytology. 
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INTRODUCTION 
 
Cervical cancer is the fourth most common cancer in the world following breast, 
colorectal and lung cancers (1). It accounted for 8 % of all cancers of women and 7 % of 
cancer related mortality in 2012(2). Cervical cancer has gained importance in the past 
few decades as being one of the few vaccine preventable cancers. Moreover, there is an 
effective screening tool (Pap smear testing) for early detection and management. The 
implementation of screening programmes and HPV vaccination strategy of all young 
women have lead to significant reduction in the incidence of cervical cancer in 
developed countries compared to less developed countries.  
The cervical epithelium progresses through a series of dysplastic changes of increasing 
grades before the development of an invasive carcinoma. Papanicolaou stain was 
developed in 1928 and has been in use for the study of cervical exfoliative cytology 
since 1941. Routine Pap smear testing is advised in all women over 21 years of age and 
in 1988, Bethesda system of standardised reporting was developed. Various studies 
have aimed at assessing the sensitivity, specificity, positive and negative predictive 
values of Pap smear testing to determine its efficacy as a screening modality in 
diagnosing the premalignant and malignant lesions of cervix. It was found that Pap test 
has a variable sensitivity and reasonably high specificity, positive and negative 
predictive values.  
Colposcopic examination and biopsy of cervix was the next advent in the spectrum of 
preventive measures for cervical carcinomas. There are characteristic histological 
changes associated with each grade of cervical intraepithelial neoplasia. However, there 
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was a high interobserver variability and low reproducibility in interpreting the cervical 
biopsies. 
The identification of Human Papilloma Virus in 1976 as a causative agent in the 
development of cervical cancers was a landmark discovery in the history of cervical 
tumourigenesis. HPV DNA testing in the cervical scrape became the molecular method 
of screening for cervical cancer due to its high sensitivity. However, it was noted that 
HPV prevalence is high in women younger than 30 years of age and the mere presence 
of the virus does not translate into a neoplastic process. Hence, HPV testing as a routine 
screening technique was not recommended in young women due to its low specificity 
and high cost. 
It was important to correctly identify the grade of cervical intraepithelial neoplasia 
(CIN) as the treatment and prognosis differ in various subtypes. It became essential to 
develop a marker for dysplasia with a high sensitivity, comparable to HPV DNA testing 
and high specificity comparable to cytology. When the molecular mechanism by which 
HPV causes cervical cancer was extensively studied,  it was found that the viral 
oncoproteins E6 and E7 dysregulate the tumour suppressor proteins p53 and Rb. E7 
after binding to Rb protein releases E2F-1 transcription factor, in turn causing elevated 
levels of  p16, which is a cyclin dependent kinase inhibitor. Thus, it was logical to 
conclude that p16 would be an ideal candidate as biomarker to detect cervical dysplasia. 
A number of studies have investigated the role of p16 in cytological and 
histopathological samples in various squamous and glandular lesions of cervix. Majority 
of the studies have confirmed the over expression of p16 in squamous and glandular 
dysplasia(3). It has also been proven that p16 can discriminate the benign mimics from 
preneoplastic and neoplastic conditions.  
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It was found that the concurrent use of p16 immunohistochemistry improved the 
interobserver agreement and reproducibility in the diagnosis of premalignant lesions of 
cervix (4). It was also believed that as p16 over expression occurs as a result of cell 
cycle dysregulation following HPV infection, it can be used to establish cervical origin in 
adenocarcinoma of the pelvic region (5). 
It is widely known that even though HPV colonisation is highly prevalent in young 
women, 90 % of them clear within 2 years and only 10 % progress into neoplasia. 
Studies have been done to investigate the role of p16 in predicting the outcome of the 
premalignant lesion and to assess the metastatic potential of carcinomas(6). 
Majority of studies which have tried to develop a panel of immunohistochemical 
markers for cervical carcinoma have included p16 in the primary panel. It is also 
suggested that p16 immunohistochemistry can be complemented by MIB-1 
proliferation index and other newly recognised markers such as cyclin D1, ProExC, 
cyclin E and p21 to improve the diagnostic accuracy. 
Thus, various studies have investigated the role of p16 immunohistochemical marker in 
cytological and histological samples to establish a diagnosis of cervical dysplasia by 
differentiating it from various benign mimics, to ascertain primary malignancy in cervix 
and to predict the outcome of the disease in terms of progression into a higher grade 
lesion and metastatic potential. 
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REVIEW OF LITERATURE 
 
Epidemiology 
Cervical cancer ranks fourth among all the other cancers in the world following breast, 
colorectal and lung cancers. According to the statistical information provided by the 
World Cancer Research International,  5,28,000 new cases of cervical cancer were 
diagnosed all over the world in 2012. Globally, it accounted for 8% of all cancers of 
women and 7% of cancer related deaths in that year. Developing countries faced the 
highest disease burden with an incidence of 4, 45,000 (84%) of the new cases diagnosed 
in a year of which about one fifth were diagnosed in India. The highest incidence rates 
were observed in Sub-Saharan Africa, Latin American and Caribbean countries and the 
lowest incidence rates were noted in North America and Oceania (1).  
The highest age adjusted rate per 1, 00,000 population was in Malawi (75.9) followed 
by Mozambique (65.0) and Comoros (61.3). Squamous cell carcinoma accounted for 
80% of cervical cancers, adenocarcinoma, about 15% and other carcinomas like 
adenosquamous, small cell and neuroendocrine together amounted to 5%. According to 
the data provided by SEER programme (Surveillance, Epidemiology and End Result) by 
National Cancer Institute, 0.7% of all cancer related deaths were due to cervical cancer. 
Five year survival rate (2004 to 2010) was found to be 67.9%. The incidence rates have 
been falling at an average rate of 1.2% per year and death rates by an average of 1.3% 
per year over the past 10 years (2002 to 2011) owing to effective surveillance and 
screening programmes. Life time risk of developing cervical cancer was found to be 
0.7%(7). 
GLOBOCAN 2012, an international agency for cancer research maintained by World 
Health Organisation (WHO) states that up to 70 % of global burden of cervical cancer 
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mortality falls on less developed countries and more than 20 % of new cervical cancer 
cases are diagnosed in India. A drastic difference in the incidence of cervical cancers 
was noticed between North America and sub Saharan Africa (6.6 vs. 34.8 per 1,00,000 
women) and it was attributed to effective screening programmes enabling early 
detection and management(2). 
In European cancer registry, the crude incidence rate was estimated to be around 10 
new cases per 1, 00,000 females. The age of diagnosis ranged from 25 to 64 years. A 
drastic reduction in incidence was observed from 1988 onwards due to successful 
cervical screening programmes. 1 in 134 is estimated to be the lifetime risk of a woman 
to develop cervical cancer in UK. 66 % of the cases were squamous cell carcinoma and 
15 % were adenocarcinoma(8). 
In 2012, Dikshit et al studied the cancer mortality rate in India. The most common cause 
of cancer death in Indian women between 30 – 69 years of age was found to be cervical 
cancer (17.1%). It was also found that cervical cancer was less common in Muslim 
women than in Hindu women. The death rate due to cervical cancer was estimated to be 
16 per 1, 00,000 women. Thus a 30 year old Indian woman has a 0.7 % risk of dying due 
to cervical cancer before the age of 70(9). 
The National Cancer Registry Programme maintained by Indian Council of Medical 
Research states that Chennai urban population based registry shows the highest 
incidence of cervical carcinoma in India with an age adjusted incidence rate of 30.6 per 
1, 00,000 women. However, district based registry showed the highest incidence in 
north eastern districts of Tamil Nadu (Age adjusted Incidence rate: 39.2 per 1, 00,000 
women). This was noted in the following districts in descending order: Pondicherry, 
Villupuram, Cuddalore, Thiruvallur and Chennai. Among the urban population, Chennai 
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topped the list followed by Chandigarh (AAR: 26.9 / 1,00,000),  Bhopal (22.2/ 1,00,000),  
Bangalore (19.8 / 1,00,00),  Mumbai (15.4 / 1,00,000 ), Delhi (13.7 / 1,00,000) and 
Kolkata (13.0 / 1,00,000)(See Figure 1).  Lowest incidence was noted in Jammu & 
Kashmir and north eastern states like Arunachal Pradesh and Manipur.  Figure 2 shows 
comparison of incidence rates in various cities in India with that of other countries (10). 
 
Figure 1: Comparison of age adjusted incidence rates between districts in India 
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Figure 2: Comparison of age adjusted incidence rates of urban population based registry 
in India with that of other countries. 
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Normal anatomy, embryology and histology 
The cervix is a fibromuscular cylindrical structure present in the lower portion of 
uterus, measuring about 2.5 to 3cm in length. A part of it is located above the vaginal 
vault whereas the remaining portion protrudes into the vagina. It develops from the two 
paramesonephric ducts by 6th week of gestation. By 12th week, the outer parts of the 
two ducts fuse to form a urogenital sinus which gives rise to cervix and uterus. The 
outer surface of the ectocervix is covered by stratified squamous epithelium, which 
continues into the vaginal mucosa. The endocervical canal consists of endocervical 
glands lined by mucin producing columnar epithelial cells, which merges with the 
stratified squamous epithelium of ectocervix in the lower end and continues into the 
lower uterine segment in the upper end, thus forming a bridge between vagina and 
endometrial cavity. This property of abrupt transition from one type of epithelium to 
another type makes the cervix vulnerable to dysplasia. Hence, a detailed understanding 
of the normal histology and progressive changes that occur to it is essential (11)(12). 
Epithelium of the ectocervix: Sexually mature epithelium of ectocervix is non 
keratinised and is composed of mainly three layers of cells each with a characteristic 
morphology -  the lower one third is formed by basal / parabasal cells, the middle one 
third by intermediate cells and the upper one third by superficial cells. The number of 
cells in each layer and the predominant cell type varies with age and the phase of 
menstrual cycle. Normal stratified squamous epithelium of the ectocervix demonstrates 
a differentiation sequence from the basal cells to superficial cells. In general, as the 
differentiation progresses the cells acquire more cytoplasm, the nuclei become smaller 
and the chromatin becomes paler(12)(13). 
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The basal layer is two to three cell layers thick and rests on a basement membrane. The 
cells are almost spherical, have an oval to round nucleus with an average size of 50 
microns, which is perpendicular to the basal lamina with dense chromatin. Mitotic 
activity is usually inconspicuous. The parabasal cells are one to two layers thick, with 
nuclear size of approximately 40 to 45 microns and contain more cytoplasm compared 
to basal cells. These cells proliferate actively and hence mitotic figures are usually seen. 
The predominant function of these cells is regeneration of epithelium. Basal cells 
function as stem cells and parabasal cells form the replicating component. Hence these 
cells express epidermal growth factor receptors such as HER 2 neu, estrogen and 
progesterone receptors(11). 
The middle one third is occupied by intermediate cells. They are polyhedral in shape, 
nuclear size measuring approximately 35 microns and exhibits gradual increase in 
volume of cytoplasm. The striking feature of these cells is that they begin to accumulate 
glycogen, thus rendering the cytoplasm clear and abundant, making them Periodic Acid 
Schiff positive and diastase labile. The nuclear size is stable up to the most superficial 
layer. These cells do not replicate. The significance of intermediate cells is that they can 
sometimes simulate koilocytic cells, leading to misinterpretation. 
The top most layer is formed by superficial cells characterised by tiny pyknotic dot like 
nuclei, about 25 microns in size and contain abundant cytoplasm. This represents the 
most differentiated layer. Keratinisation can occur only in the superficial and 
intermediate cells. 
In prepubertal and post menopausal women the squamous epithelium is atrophic due 
to lack of estrogen exposure. The predominant cell type seen is parabasal cell. There is 
no accumulation of intracytoplasmic glycogen. The significance of this is that it can be 
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confused with cervical intraepithelial neoplasia in cytology specimens. In sexually 
mature women, due to the presence of active form of estrogen, estradiol 17 beta, there 
is constant remodelling of the epithelium by proliferation, differentiation and 
exfoliation. A new population of cells is formed every 4-5 days. Progesterone inhibits 
maturation at the level of intermediate cells. Therefore, in the follicular phase of 
menstrual cycle, the predominant cell type seen on exfoliative cytology would be 
superficial cells, whereas in the luteal phase, it would be intermediate cells. During 
pregnancy, due to elevated levels of circulating progesterone, the intermediate cells 
predominate. The age and the phase of the menstrual cycle have to be borne in mind 
while interpreting exfoliative cytology to avoid a misdiagnosis(11)(13). 
Mucin producing columnar epithelial cells line the surface as well as the glandular 
component in the endocervix. The columnar epithelial cells are tall with basally located 
nuclei, granular chromatin and vacuolated cytoplasm. The mucin stains for Periodic 
Acid Schiff and Alcian blue due to the presence of sulphated mucopolysaccharide. They 
are simple epithelia and express low molecular weight cytokeratins 7, 8, 18 and 19. 
Mitosis is usually absent. Ciliated cells are usually present. The cervical stroma is 
composed of fibrous connective tissue along with elastic fibres running parallel to 
smooth muscle bundles. An occasional lymphoid aggregate may be present. The sub-
epithelial capillary network is well formed in the endocervix(11). 
The cervix lies between the sterile environment of endometrial cavity and the microbial 
environment of vagina and hence has a strong immune apparatus. Other cells normally 
present in the cervix include Langerhans cells and cells of immune system as a part of 
host defence against bacterial and viral organisms. IgA antibody mediated, IgG antibody 
mediated and cellular immune systems are seen in the cervix. CD 8 positive T 
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lymphocytes are the predominant cells present followed by variable numbers of 
dendritic cells and B lymphocytes (13)(12). 
Transformation zone: The squamocolumnar junction or the transformation zone is the 
point of transition between the stratified squamous epithelium of ectocervix and mucin 
producing columnar epithelium of endocervix. At birth, columnar epithelium lies in the 
ectocervix in majority of infants but it migrates into the endocervical canal soon after 
and remains there until menarche. However, with onset of puberty, the columnar 
epithelium moves again into the ectocervix, more towards the anterior region than the 
posterior. This is thought to occur due to swelling of cervical stroma under estrogenic 
stimulation which causes disproportionate increase in the bulk of uterus. This pulls the 
endocervical mucosa into the ectocervix and is referred to as ectropion. The exposed 
endocervical mucosa appears ulcerated and red to the naked eye. After this 
physiological ectropion, there is gradual replacement of columnar epithelium by 
stratified squamous epithelium during the reproductive years, thus forming the 
transformation zone which is the junction between the two different types of 
epithelia(12). 
There are two types of squamocolumnar junction – the original transformation zone is 
the region where the native stratified squamous epithelium meets the endocervical 
columnar epithelium which is present in the ectocervix during reproductive years. After 
squamous metaplasia of columnar epithelium has occurred, the native squamocolumnar 
junction is the conversion point between the new and original squamous epithelium. 
The point where there is active replacement of columnar cells by squamous cells is the 
functional transformation zone. It often has an irregular contour and there is 
enlargement of the transformation zone during pregnancy and following estrogen 
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therapy. In short, in the early reproductive years, the functional transformation zone is 
near the anatomical external os and in the perimenopausal years, it lies deep in the 
endocervical canal away from the external os(12). 
Two mechanisms have been proposed for migration of squamocolumnar junction – the 
direct ingrowth of native stratified squamous epithelium into the endocervix, pushing 
the columnar cells and dislocating them from the basement membrane which causes 
them to slough off. The second mechanism involves proliferation of reserve cells and 
their differentiation into squamous cells rather than columnar cells. The exact 
mechanism however is still not known(12). 
The transformation zone is a region of active replication and replacement of 
endogenous epithelium thus making it highly susceptible to neoplastic transformation. 
The squamocolumnar junction can be seen with the aid of a colposcope, thus enabling 
the clinician to visualise structural changes that accompany neoplastic process, making 
it a valuable tool for early detection of intraepithelial neoplasia(14). 
Knowledge of lymphatic supply of cervix is essential for sampling of lymph nodes in 
case of neoplasia. There are three major locations into which lymphatic drainage from 
cervix occurs – external iliac lymph nodes laterally, internal iliac lymph nodes 
posterolaterally and rectal and sacral nodes posteriorly. The descending branch of 
uterine artery forms the arterial supply and venous drainage is into the uterine vein. 
The pelvic splanchnic nerves (S2-S3) provide the nerve supply(12). 
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Morphological variants of cervical carcinoma: 
Squamous cell carcinomas are usually exophytic masses that grow into the surface as 
polypoidal or papillary projections or can occasionally be endophytic lesions. They are 
broadly divided into two categories: keratinising and non keratinising depending on the 
evidence of keratin production. Verrucous carcinoma is a very well differentiated 
variant with an undulating and warty appearance. The neoplastic cells have abundant 
cytoplasm and features of HPV related changes are usually not conspicuous. Warty or 
condylomatous variant on the other hand, shows florid features of HPV infection like 
koilocytic change, multinucleation, papillomatosis, acanthosis, nuclear hyperchromasia 
and enlargement. Papillary variant shows broad and thin papillae of dysplastic cells 
extending into the stroma. They are usually associated with HPV 16.  They lack cellular 
features of HPV and keratinisation. Basaloid squamous cell carcinoma is an aggressive 
variant and is usually associated with HPV 16. They are composed of nests of basaloid 
immature looking cells with focal evidence of keratinisation. Lympho-epithelioma like 
variant is composed of uniform small cells with vesicular nuclei, prominent nucleoli and 
scant cytoplasm in a background of lymphocytes. It differs from other variants in that 
the etiology is thought to be Epstein Barr Virus infection rather than HPV(15). 
Adenocarcinoma can also present as exophytic masses in 50 % of the cases, others 
cause nodular enlargement and deep infiltration causing barrel shaped cervix. 15% do 
not cause visible lesions. Primary endocervical adenocarcinoma has to be distinguished 
from endometrial carcinomas by immunostaining for CEA and negative staining for ER, 
PR and vimentin. The commonest variant is mucinous adenocarcinoma, of which 
endocervical type accounts for about 70% of glandular neoplasms. Coexisting CIN can 
occur in up to 40 % of cases. They are usually well to moderately differentiated 
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tumours. Intestinal variant shows goblet cells and less frequently endocrine and Paneth 
cells. Minimal deviation type is a rare extremely well differentiated adenocarcinoma 
composed of glands lined by bland cells with occasional cells displaying moderate 
atypia and mitosis and are deeply invasive. It is difficult to make the diagnosis on punch 
biopsies. It is characterised by somatic mutation of STK 11, the gene that is responsible 
for Peutz Jeghers syndrome. The villoglandular variant shows frond like growth pattern 
and are usually well to moderately differentiated tumours. Endometrioid carcinomas are 
distinguished from uterine primary by less conspicuous squamous elements and little 
intracellular mucin. Clear cell carcinoma shows hob nailing of cells with solid, papillary 
or tubulocystic pattern (16). 
Other less common variants: Adenosquamous carcinoma is composed of closely 
intermingled malignant squamous and glandular components. Glassy cell variant is a 
poorly differentiated tumour with a prevalence of 1-2 %. The neoplastic cells are large 
with distinct cell margins and ground glass cytoplasm. Adenoid cystic carcinoma of 
cervix show greater nuclear pleomorphism, necrosis and high mitotic rate compared to 
its counterpart in the salivary gland. Mesonephric variant is poorly differentiated and 
lack intracytoplasmic mucin and glycogen. Serous adenocarcinoma of cervix is identical 
to papillary serous carcinoma of ovary and endometrium and consists of complex 
papillary pattern with budding, atypical nuclei and psammomatous bodies. Another 
extremely rare variant is hepatoid adenocarcinoma (15). 
Neuroendocrine tumours encompass a spectrum including carcinoid, atypical carcinoid, 
small cell and large cell carcinoma. They are differentiated based upon the mitotic 
activity and nuclear atypia. They are positive for neuroendocrine markers like neuron 
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specific enolase, synaptophysin and chromogranin. Undifferentiated carcinomas are the 
ones that do not show differentiation towards any specific lineage (14). 
Viral oncogenesis and association of Human Papilloma Virus with cervical 
neoplasia. 
The association of cervical neoplasia with Human Papilloma Virus is universally 
accepted. Various studies have proven that colonisation of oncogenic HPV DNA in the 
cervical epithelium precedes the development of cervical intraepithelial neoplasia. 
Human Papilloma Virus is made of a single molecule of circular double stranded DNA, 
measuring 8 kilo bases. To date, more than 100 HPV subtypes have been identified. 
Oncogenic HPV types are defined as “those which are associated with cervical or anal 
cancer and include HPV types 16, 18, 31, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82”. 
The non oncogenic types, HPV 6, 11, 40, 42, 54 and 55 cause skin or mucosal warts. Of 
all the subtypes, HPV 16 is the commonest oncogenic strain with highest potential for 
persistence and malignant transformation of epithelial cells. HPV 16 is also the most 
frequently associated strain in case of squamous cell carcinoma whereas HPV 18 is the 
commonest strain detected in adenocarcinoma (11)(14). 
Knowledge of HPV genome and gene protein interactions in host is essential to 
understand the role of p16 in cervical neoplasia. Almost all cervical cancers are caused 
by high risk HPV, most commonly the HPV 16 and 18 subtypes.  
HPV genome: It consists of three coding regions required for viral replication and 
production of capsid protein envelope. The early (E) period of life cycle require 2 coding 
regions with six open reading frames (ORF) - E1, E2, E4, E5, E6, E7 which encode 
proteins required for transcription, replication, host cell transformation and integration 
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with host genome. The late (L) region encodes structural proteins (L1, L2). Non Coding 
Region (NCR) is involved in RNA synthesis and controls the expression of ORF(14). 
E1 acts as DNA dependent ATPase and ATP dependent helicase. E2 is responsible for 
separation of HPV DNA into daughter and host cells. E6 and E7 are the proteins which 
impart oncogenicity to HPV.  They are expressed in virtually all cervical neoplasias. 
They encode proteins which induce proliferation and transformation of keratinocytes. 
E6 protein binds to p53 and destroys it through ubiquitin dependent mechanism.  p53 is 
a tumour suppressor gene that causes cell cycle arrest if DNA damage occurs. So the 
primary function of E6 is prevention of apoptosis. It also stimulates the expression of 
TERT which is the catalytic subunit of telomerase that removes the check in cell cycle 
thus causing immortalisation of cells. E7 binds to retinoblastoma protein causing 
dissociation of E2F-Rb complex and subsequent degradation of proteins. This triggers 
cell division by causing increased expression of enzymes required for nucleotide 
biosynthesis and cyclins that are required for progression through S phase in cell cycle. 
Thus, E7 mainly increases the rate of cell division. E7 and E6 proteins complement each 
other in their functions. E7 also causes inactivation of cyclin dependent kinase 
inhibitors p21 and p27 causing increased CDK4/cyclin D. Thus, the presence of E7 is 
implicated in the development of benign tumours and the presence of E6 in the 
development of malignant neoplasm(11). 
HPV Life Cycle:  
The transformation zone of cervix is the region where HPV infection begins and most of 
the neoplastic processes occur. In this region, HPV enters the basal or reserve cells 
through minor defects. The prevalence of HPV infections peaks between 20 to 24 years 
of age while there is a subsequent decline in prevalence due to development of 
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immunity against the virus. 90% of HPV infections are cleared within 2 years by the 
host immune response. The remaining proceeds to become (1) productive infection (2) 
abortive infections or (3) latent infections. In the productive infection, there is 
replication of the virus which kills the cells. In latent infections, there is persistence of 
virus in cytologically normal cells. The basal layer harbours HPV in the form of 
episomes (extra chromosomal DNA).  Complete viral replication occurs only in 
epithelium undergoing terminal differentiation. Koilocyte formation can occur only in 
cells which are at least partially mature. Abortive infections occur when the virus in 
unable to complete its life cycle with integration of viral DNA into the host genome. This 
is thought to be the mechanism behind progression of CIN 3 to invasive carcinoma. 
Affinity of E7-Rb binding is considerably lower in low risk HPV and E6 protein may not 
bind to p53. Hence, the cell cycle dysregulation may occur by interfering with Notch 
signalling pathway(14). 
In spite of the high incidence of HPV in sexually active women, there is a 
disproportionately low prevalence of cervical carcinoma. Therefore, it was concluded 
that a number of environmental factors also play an important role for transformation 
of HPV infected cells into a neoplastic process. The most important factors whose causal 
association have been proven are age of first sexual intercourse, number of partners, 
smoking, presence of sexually transmitted infections and immune status of the host. 
A study done by Donna Dehn et al in 2007 investigated the different HPV detecting 
methods and relevance of molecular markers. The methods used were Direct 
Hybridisation, Hybrid capture 2, type specific PCR amplification, third wave invader 
genotype assay, viral load real time PCR and p16 immunohistochemistry. Hybrid 
capture 2 was found to be the best method with a sensitivity of more than 96% and 
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specificity of 61% in CIN 2 lesions. p16 immunohistochemistry had a sensitivity of 
81.1% and specificity of 95.4 % for CIN 2 lesions. The authors proposed the use of p16 
as a surrogate marker for detecting dysplastic lesions of cervix. ProExC was an 
emerging new method that included TOP2A and MCM2 molecular markers for detection 
of cervical dysplasia(17). 
Another study done by Zhang Sheng et al in 2013, aimed at detection of subtypes of HPV 
in cervical glandular lesions using In situ Hybridisation, Polymerase Chain Reaction and 
p16 protein expression by immunohistochemistry. They concluded that a combination 
of ISH and PCR is superior to p16 IHC in detecting high grade cervical intraepithelial 
lesions(18). However, the cost effectiveness of each has to be borne in mind. 
A study done by Deodhar et al in 2012 at Tata Medical Centre, Mumbai tried to identify 
the prevalence of subtypes of HPV in cervical lesions in rural Indian women. It was 
found that the overall prevalence of high risk Human Papilloma Virus in inflammatory / 
cervical intraepithelial neoplasia grades 1, 2 and 3 and invasive cancers was 37.6%, 
63.5%, 97.2% and 92% respectively. 80.6% and 86.5% of CIN 3 and invasive cancers 
showed the presence of HPV 16 and 18. HPV was detected in 94.7% and 84.4% cases of 
invasive cancers and high grade intraepithelial lesions which showed diffuse strong 
positivity for p16 immunohistochemistry(19). 
As the role of Human Papilloma Virus in cervical tumourigenesis was indisputably 
established, large number of studies were done to elucidate pathogenesis and to 
characterise the cell regulatory proteins which are disrupted due to the presence of 
virus. Moreover, direct viral detection, even with high sensitivity was expensive and 
hence cannot be routinely employed as a diagnostic tool in the general population. It 
will also require referral to tertiary care centres. Relying on histomorphology alone also 
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had its disadvantages in that it had substantial interobserver variability. It was logical to 
regard immunohistochemistry as an optimal confirmatory tool.  Therefore, it became 
imperative to develop a surrogate marker for cervical dysplasia with sensitivity 
comparable to HPV DNA detection and specificity comparable to cytology. 
In 2003, an elaborate study with respect to molecular markers in gynaecological 
oncology was done in Germany by Langosch et al. It was found that the main pathway of 
tumourigenesis was E6 and E7 viral protein expression leading to increased 
inactivation of tumour suppressor proteins p53 and Rb. This causes increase in the 
expression of cyclin dependent kinase inhibitor p16 which in turn causes inactivation of 
Rb due to negative feedback transcriptional control. Thus, cells proliferate with no CDK 
inhibitory effect in the presence of high levels of p16. High risk HPV infected cells also 
cause increased levels of cyclin E and cyclin dependent kinase 2, thus activating 
p21/p27-cyclin E/CDK2. It was found that there is down regulation of p21 and 
upregulation of p27 in most cervical premalignant lesions. It was also observed that 
there is over expression of CDC25A which activates CDK2. There is enhanced expression 
of proteins that control S phase, namely, cyclin A, cyclin B and CDC2. Out of all the 
proteins studied, p16 and cyclin E showed the most prominent upregulation(20). 
The molecular basis for HPV induced carcinogenesis identifies various mechanisms that 
cause immortalisation of cervical epithelial cells (See Figure 3): 
 (a) Ability to produce genomic instability by causing monosomies and trisomies, 
chromatid breaks and gaps more commonly found in chromosomes 1, 3 and 5. The 
ability of the virus to integrate with the host genome is thought to be due to acquisition 
of chromosomal instability.  
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(b) Arrest of DNA damage response: this is thought to be due to interference with p53 
mediated arrest of cell cycle and inactivation of p21. This causes accumulation of 
genetic changes which might increase the oncogenic potential of the virus.  
(c) Ability of HPV to redirect suprabasal cells to continue DNA synthesis causing 
increased production of progeny viral genome through amplification. 
(d) Continued expression of activated Ras which causes increased viral protein 
expression. 
(e) Integration in HPV in proximity to MYC causing c-myc amplification which is 
observed more frequently in invasive cancers compared to benign and premalignant 
lesions. 
(f)  Increased expression of Her2 neu mRNA and protein, especially observed in case of 
adenocarcinoma 
(g) Hypermethylation of gene promoters that cause down regulation of tumour 
suppressor genes 
(h) the ability to interact with other infectious agents like Herpes Simplex Virus and 
Chlamydia trachomatis.(21)  
21 
 
 
Figure 3: Mechanism of action of E7 protein and E7-Rb interaction 
WHO states that loss of heterozygosity is observed in various chromosomes like 3p, 5p, 
5q, 6p, 6q, 11q, 13q and 17q. The cases that had lymph node metastasis from cervical 
carcinomas had loss of heterozygosity at chromosomes 3p, 6p, 11q, 17p, 18q and X. 
Aberrant transcription, homozygous deletion and loss of heterozygosity of FHIT gene 
(fragile histidine triad) were also implicated in cervical tumours. Familial susceptibility 
for cervical cancers has also been observed, the largest family cluster obtained from 
Swedish family-Cancer database. The relative risk of developing cancer when daughter 
or mother was affected is 2. The familial predisposition is thought to occur due to 
involvement of genes that modulate immune response - HLA haplotypes(15). 
Prognostic and predictive factors in cervical carcinomas: 
Clinical parameters that are found to be significantly associated with worse prognosis 
are age, volume of tumour, vascular and lymphatic spread and stage of the disease. The 
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treatment is radiotherapy and surgery for tumours upto stage II A. External beam 
radiotherapy and intracavitary radiation therapy are given for stages II B to IV. A 
concurrent cisplatin based chemotherapy has shown to improve overall survival and 
disease free survival. The overall survival was increased by 16 % with combined 
chemoradiation therapy. 
Histological parameters like grade and type of the tumour are also noted. The effect of 
grade on response to treatment is controversial. Adenocarcinomas, adenosquamous and 
neuroendocrine carcinomas are said to have a worse prognosis than squamous cell 
carcinoma as the progression time from premalignant lesions to invasive carcinomas 
was shorter . 
Genetic factors: c erb 2 overexpression has a poor clinical outcome with increased 
chance of tumour recurrence. Amplification of c-myc protein is also associated with 
poor prognosis.  
Cellular biomarkers of cervical carcinogenesis 
In 2013, Tornesello et al aimed at identifying the cellular and viral biomarkers in 
premalignant cervical lesions that caused tumour progression. They analysed the 
candidate biomarkers, namely, HPV DNA, HPV E6 and E7 mRNA, HPV proteins, p16, 
MIB-1, MCM2 and TOP2A cellular factors and DNA methylation profile. The sensitivity 
of p16INK4A to identify CIN 2 or worse was 83.2% and 83.8% in ASCUS and LSIL 
cytology.  The specificities were 71% and 65.7% for CIN2 and LSIL respectively.  When 
dual staining strategy with p16/MIB-1 was employed, the sensitivity to detect ASCUS / 
LSIL increased to 92.2 / 94.2% respectively. The specificity rates were 80.6% and 
68.0% for ASCUS and LSIL respectively.  Thus p16 and MIB-1 when used in conjunction 
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showed a similar sensitivity and a higher specificity compared to any high risk HPV 
detection methods or p16 alone(22). 
A detailed study regarding the structure of p16 and its regulatory mechanisms involved 
in carcinogenesis was done by Juan Li et al. p16 has a helix turn helix configuration and 
is composed of four ankyrin repeat motifs. It is situated in chromosome 9p21. It is a 
major negative controller of cell cycle. Apart from the most widely known pRB/E2F 
pathway, there are other alternate pathways by which p16 regulate cell cycle. p16 
interacts with TFIIH, a general transcription factor required to form the pre initiation 
complex that inhibits phosphorylation of carboxy terminal domain (CTD) of RNA 
polymerase II thus causing cell cycle arrest. Additionally, p16 binds to glycine rich loop 
of c – jun – N - terminal kinases 1 and 3 and suppresses the kinase activity thereby 
interfering in cell transformation. p16 is also thought to be involved in cellular ageing as 
increased levels of p16 protein are present in aging human tissues in health as well as 
diseased states, although the exact molecular mechanisms have not yet been 
characterised. p16 deficient cells have shown to be sensitive to apoptosis induced by 
ultra violet radiation. Thus, p16 appears to be involved in the nuclear response of cells 
to genotoxic agents. Increased levels of p16 in tumour cells as a consequence of 
genotoxic DNA damage resulted in arrest of cell cycle, inhibition of apoptosis by 
preventing release of cytochrome c, depolarisation of mitochondrial membrane and 
activation of caspase cascade. p16 is the second most commonly mutated gene in 
human cancers, next to p53. The frequency of p16 inactivation in different types of 
human cancers are as follows: more than 85% in pancreatic carcinomas, followed by 50 
– 70% of head and neck squamous cell carcinomas, approximately 70% of oesophageal 
cancers, 65% of colorectal malignancies, 65% of non small cell lung cancers, 60% of 
leukaemia, multiple myelomas and melanomas and 20% of breast carcinomas. 
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There are four types of genetic alterations that are thought to affect the function of p16: 
the most frequent changes are homozygous deletion and promoter hypermethylation. 
The other changes include loss of heterozygosity and point mutation. The type of 
genetic alteration varies in different types of cancers. Expression of p16 is regulated at 
various levels; post transcriptional modification occurs at sp – 1 binding site, HBP -1 
binding site, ITSE, Ap – 1 binding site and PPRE sites. Post translational modification 
occurs by phosphorylation. The half life of p16 protein ranges from 30 minutes to three 
hours. It is degraded in a proteasome dependent manner. p16 is a member of INK4A 
family of proteins which also includes p15, p18 and p19. It is also called MTS -1 
(Multiple tumour suppressor 1) (23). 
Various studies from India have also tried to elucidate the genetic profile of cervical 
cancers. A study done by Rajkumar et al in 2011 observed up regulation of up to 20 
genes and down regulation of 14 genes in cervical tumours. Real time PCR and 
immunohistochemistry were used and differential expression of each were analysed in 
normal, CIN 1 / 2, CIN 3 and invasive squamous cell carcinomas. Following genes were 
upregulated in CIN 3 relative to normal and CIN 1 suggesting a role in early tumour 
transformation: UBE2C, NUP210, MELK, CCNB 1, CCNB 2, PLOD 2 and CDC 20. Other 
genes that were over expressed were: IL8, INDO, AGRN, DTXL, ISG 15, ISG 20, MMP 1, 
MMP 3, CCL 18, STAT 1 and TOP2A (24). 
Another study conducted in Tata Memorial hospital, Mumbai by Asha Thomas et al 
studied differential expression of various genes through progressive FIGO stages in 
Indian women. Stages I to IIA were considered early and IIB onwards as late stages. 
They observed that SPP-1 (Secreted Phosphoprotein 1) more commonly known as 
osteopontin, had shown 34.6 times overexpression in cervical carcinoma. In terms of its 
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use as a diagnostic marker, 50.6% sensitivity and 95.0% specificity were obtained. It 
also correlated significantly with overall survival and disease free survival (p values 
0.002 and 0.033 respectively). It was also noted that there was increasing expression of 
PCNA (Proliferating cell nuclear antigen) through progressive grades of dysplasia.  
There was down regulation of apoptosis related genes like 
IP3,  BCL2L11,  TNFSF13,  PERP,  ATF6,  BPT and phosphatases DUSP1,  PPP2R5E,  PTPN4 
were underexpressed. The genes involved in transcriptional activation, 
ATF2,  GTF3C1,  TFE3,  MCRS1 and signalling and migration of cells (MAPRE3,  PAK and 
PIK3R1) were overexpressed in advanced stage as compared to early-stage cervical 
cancer (25). 
A review was done by Gupta et al on biomarkers in cervical tumours. The sensitivity and 
specificity of p16 immunohistochemistry to detect high risk HPV were found to be 84 % 
and 98 % respectively. The positive predictive value was 97 % and negative predictive 
value was 86 %. High risk HPV positivity was detected in 93 % of p16 positive CIN 1. 
Widespread expression of p53 and p21 were seen in low risk HPV subtypes. p53 is 
thought to be a predictor for rate of regression in CIN 3 cases. However, Retinoblastoma 
protein expression is considered a stronger predictor for progression of cervical 
intraepithelial lesions into a higher grade. It was also demonstrated that addition of CK 
13 and CK 14 to the panel of markers helped to identify the subgroups that had a higher 
risk of progression. Telomerase activity did not reflect rate of progression. Loss of FHIT 
expression was associated with increased rate of progression. ProExC which is a 
combination of minichromosome maintenance 2 and topoisomerase IIA were found to 
be a better positive predictor for rate of progression than p16. MCM5 intensity did not 
correlate with the presence of high risk HPV infection, thus making it a valuable 
biomarker for HPV independent cervical dysplasia. CDC6 was not detected in low grade 
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cervical lesions, thus restricting its use only for the detection of high grade lesions and 
invasive carcinomas. Thus, it was concluded that a combining p16, ProExc and MIB-1 
proliferation index along with high risk HPV DNA detection formed the best panel to 
detect lesions that would progress (26). 
 
One of the major challenges in the interpretation of cervical biopsies is to distinguish 
benign and reactive conditions from dysplastic lesions. There are various benign mimics 
of neoplasia. The most notable amongst them is radiation induced changes which can be 
easily mistaken for neoplasia. Complex architecture and cribriform patterns with 
nuclear hyperchromasia and enlargement may be present even after 18 years of 
completion of radiation therapy. However, the molecular and immunophenotypic 
features described above are usually absent.  
Acute and chronic cervicitis may mimic carcinoma on colposcopic examination due to 
their congested and inflamed appearance. Various microorganisms, most commonly 
Trichomonas vaginalis, Chlamydia trachomatis, Herpes simplex, bacterial vaginosis can 
cause marked inflammation and reparative changes which can resemble carcinoma.  
Cervix is also a site for the development of various metaplastic lesions. Squamous 
metaplasia is so consistent a finding that it is considered a normal physiological 
response to ectropion. Tubal, endometrioid, intestinal and transitional cell metaplastic 
changes are the other conditions that can occur in cervix. 
The glandular compartment can also undergo various reactive changes which can 
confuse inexperienced pathologist. Notable amongst them is microglandular 
hyperplasia and endocervical tunnel clusters. Microglandular hyperplasia consists of 
small closely packed glandular structures lined by columnar cells with bland nuclei. 
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Endocervical tunnel clusters are small endocervical glands arranged in a lobular 
configuration (14). 
Thus cervical lesions range along a spectrum of benign and reactive conditions through 
increasing grades of CIN 1, 2 and 3 and invasive squamous cell carcinomas. The 
endocervical lesions encompass reactive conditions like microglandular hyperplasia, 
cervical glandular intraepithelial neoplasias, low grade and high grade and invasive 
adenocarcinoma. The fact that these lesions progress over a fairly well defined time 
period with most of the lesions demonstrating a definite viral etiology make them 
potentially preventable. Various methods were tried and tested for early detection of 
premalignant lesions. The evolution of Pap test was a historical landmark which proved 
to be a highly effective screening tool which drastically reduced mortality due to 
cervical cancer in developed countries.  
Pap test was discovered and named after Georgios Papanikolaou in 1928. The 
development of exfoliative cytology and routine use of Pap stain began in 1941. 
Conventional smears and liquid based cytological smears are commonly used. The 
Bethesda system was introduced in 1988 and is the most widely accepted method for 
reporting cervical cytology specimens to ensure uniform terminology. It has been 
revised in 1991 and 2001 incorporating various modifications. 
The current recommendations for cytological screening vary in different countries 
depending upon the prevalence and incidence of the disease. In general, the first 
cervical cytology should be performed at 21 years of age or within 3 years of first sexual 
intercourse and repeated every 3 years. After 30 years of age, women with negative 
cytology and absent HPV infection should be screened every 5 years. Pap test should be 
repeated every 6 to 12 months in women who harbour high risk HPV even in the 
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presence of normal cytology. If cytological abnormality is detected on Pap test, the 
patient is advised to undergo colposcopic biopsy. Low grade lesions may be followed 
up; however, ablative cryotherapy is advised, especially in cases where the patients are 
unlikely to come for follow up. High grade lesions should be treated with conisation. 
Pelvic and abdominal imaging should be done for invasive carcinomas to ascertain the 
stage of disease (27). 
 Briefly, the Bethesda system of classification 2001 is based on the severity of dysplasia 
of intraepithelial and glandular lesions. The adequacy of the specimen needs to be 
mentioned.  It is classified into broad categories: negative for intraepithelial lesion / 
malignancy, epithelial cell abnormality - squamous and glandular.  
Epithelial cell abnormality, squamous is further classified into low grade and high grade 
squamous intraepithelial lesion and squamous cell carcinoma. The equivocal category, 
Atypical Squamous Cells is further divided into “Undetermined significance” and 
“cannot exclude HSIL”. Epithelial cell abnormality, glandular is divided in to Atypical 
glandular cells – endometrial, endocervical, not otherwise specified or favour 
neoplastic, Adenocarcinoma in situ and Adenocarcinoma (28). 
The Bethesda system estimates the accuracy rate of LSIL to be 80 %. Of the remaining 
20 % which are misinterpreted, 33 % belong to a high grade category.  
According to a study done by Nguyen et al, the Bethesda system of reporting has a 
specificity of 90-99% and around 85% sensitivity to detect cervical dysplastic lesions. 
The false negative rate was found to be approximately 20% and was attributed to 
screening error and sampling error(29). 
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Denny et al compared various screening techniques for cervical neoplasia in developing 
countries including India in terms of sensitivity, specificity, availability and cost 
effectiveness.  It was observed that at a given point of time, 75 % of women had 
undergone cervical screening at least once in the last 5 years in developed countries 
compared to less than 5 % in developing countries. It was found that cytology had a 
high specificity (91 - 96 %) more than that of visual inspection methods with acetic acid 
and Lugol’s Iodine (45 – 86 %) and moderate sensitivity (44 – 78 %) compared to HPV 
DNA testing (66 - 100 %).  The study concluded that incorporation of visual inspection 
methods along with cytological screening in India would improve the detection rate of 
cervical abnormalities. The Government of India has formed a task force to ensure the 
introduction of visual inspection method by acetic acid in 50 districts in the next  5 
years (30). 
Another study done by Ansari et al in 2011 focussed on the utility of Pap smear in 
detecting the distribution of premalignant and malignant lesions of cervix in 
premenopausal women. The overall sensitivity of Pap test in detecting high grade 
dysplasia was 70-80%. It was also observed that there was increasing incidence of high 
grade dysplasia with increasing age. The established risk factors like multiple sexual 
partners, early age of sexual intercourse and concurrent sexually transmitted infections 
were found to be significantly associated with cervical dysplasia. HPV infection 
screening showed a higher sensitivity compared to cytology. However, it was concluded 
that in Indian setting, cervical cytology was a more cost effective and efficient tool to 
detect cervical dysplasia (31).  
When cytology and HPV testing were compared in American population, Pap smear and 
HPV test had a sensitivity of 55.4 % and 94.6 % respectively and specificity was 96.8 % 
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and 94.1 % respectively. Both the tests had a negative predictive value of more than    
99 %  (32). 
An epidemiological study done in Patiala evaluated 300 routine Pap smears. 45.3 % of 
the patients were between 31 to 40 years of age. 59 % of the patients presented with 
vaginal discharge. The mean age of women diagnosed to have LSIL was 32.3 years, HSIL, 
40.5 years and invasive carcinoma 57 years.  The most common clinically visible lesion 
in patients with squamous intraepithelial lesion and invasive carcinomas was erosion 
(35.7 %) followed by cervix that bleeds on touch (28.6 %). 5 % of the smears were 
found to have epithelial abnormalities. The most common reactive condition was non 
specific inflammation (71.3 %) followed by Gardenerella (2.7 %). LSIL was detected in 
3.4 %, ASCUS in 0.3 %, HSIL in 0.7 % and squamous cell carcinoma in 1.3 % (33). 
 Women diagnosed with low grade lesion may present later with an invasive carcinoma. 
Therefore a study was done by Bofin et al which re-examined all the previous Pap 
stained slides of patients diagnosed with invasive squamous cell carcinoma. It was 
observed that first High Grade squamous lesion could have been diagnosed 4.2 years 
earlier than originally thus emphasising the need for meticulous examination and 
frequent screening compared to current guidelines (34). 
A study done by Moy et al tried to establish the efficacy of cervical cytology as a primary 
screening modality in Chinese population. The sensitivity and specificity of three 
modalities were compared, namely, (1) HPV DNA testing, (2) Pap test and (3) cotesting, 
i.e. both (1) and (2). The highest sensitivity was observed for cotesting strategy 
(99.4%). HPV DNA test alone had a sensitivity of 96.3% followed by Pap alone (80.2%). 
The highest specificity was observed for Pap test alone (93.3%) followed by HPV DNA 
(85.5%) and cotesting strategy had a specificity of 84.8 %. Among the single test 
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strategies, the sensitivity of HPV DNA was higher compared to Pap test alone. However, 
the specificity was higher for Pap test alone with a lower number of cases referred for 
colposcopy (35). 
One of the major drawbacks of Pap smear reporting was variable specificity and a 
relatively low sensitivity reported in different laboratories. The reasons for low 
sensitivity for cervical smear were studied by Farimani et al by evaluating 1224 smears. 
The reasons for low detection rates were classified into three categories: Errors while 
sampling (11.7 %) which included improper endocervical cell sampling, low density of 
cells, improper fixation and obscuring inflammation, errors in preparation of cytological 
smears (74.5 %) such as poor staining and various artefacts and errors in interpretation 
(13.8 %)  when there was discordance in interpretation among the  cytologists (36). 
Therefore, a newer modality was tried by the Zetiq cell detect staining kit which 
consists of a basophilic green stain, acidophilic red stain and a proprietary plant extract. 
The sensitivity of Thin Prep was 84.4% and that of the cell detect system was 90.6%. 
The specificity of Thin Prep was 80.0% and that of the cell detection system was 76.3%. 
Thus, Thin Prep was superior to Zetiq in terms of specificity (37). 
A quantitative survey was done to compare the performance of Thin Prep liquid based 
cytology and conventional Pap smears. The two methods had a concordance of 89 % 
and 92 % on five level and dichotomous classifications. When compared with histology, 
the sensitivity rates of Thin Prep and conventional smears were 76 % and 68 % 
respectively. The specificity rates were 86 % (Thin Prep) and 79 % (conventional 
smears) (38). 
Another elaborate study was conducted by Renshaw et al to detect sensitivity in 
gynaecological cytology. The study also aimed at analysing various ways to increase the 
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sensitivity, namely, rescreening of conventional smears, second thin layer preparation, 
repeat Pap smear at a subsequent time and biopsy. The overall sensitivity of Thin Prep 
was 50-75%. On addition of rescreening strategy, the sensitivity increased to 84%. The 
sensitivity increased to 90% with second thin layer preparation and repeat Pap smear. 
This was thought to be due to interobserver variability (28-72%) and technical reasons 
such as difference in quality of staining. Therefore, the study confirmed the use of 
cervical cytology as a primary screening tool and proposed the development of a 
surrogate marker for a more objective evaluation (39). 
The test limitations and errors of interpretation of cervical cytology were analysed in a 
study done by Ronco et al. The sensitivity of cytologists in detecting HSIL was 100% and 
LSIL was 67% when the slides were reviewed by expert supervisors. Biopsy cytology 
correlation was also assessed and it was found that 88% of CIN 2/3 cases and 74% of 
CIN 1 cases were detected by cytologists in Pap smears (40). 
Another study tried to demonstrate if there was an additional benefit if a repeat Pap 
smear was performed at the time of colposcopy in detecting high grade lesions. The Pap 
smear and biopsy results were independently reviewed and a repeat Pap smear was 
performed at the time of colposcopy.  It was found that only 2% of the patients had 
significant change in management as a result of repeat smear. It was concluded that Pap 
smear done at the time of colposcopic biopsy did not yield a better result compared to 
the diagnostic smears that were taken earlier (41). 
Follow up with biopsy and high risk HPV testing was done by Faye et al in all cases 
diagnosed as HSIL on cytology. 96.0% cases of HSIL were positive for high risk HPV. 
72.3% of high risk HPV positive HSIL cases, on biopsy showed CIN 2/3, whereas only 
33.3% of high risk HPV negative HSIL cases showed CIN 2/3, raising the possibility of 
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benign mimics of HSIL. It was also observed in this study that incidence of high risk HPV 
reduced slightly with increasing age (42). 
In a cytohistological study done in St Joseph’s health centre, Canada, the sensitivity of 
cytology in detecting cervical dysplasia was 88.5%. 100 ASCUS cases were studied. In 
case of ASCUS, favour dysplasia, the sensitivity was 73% and ASCUS favour reactive it 
was 27%. Among the cytological features assessed, nuclear membrane irregularity was 
the only feature predictive of dysplasia. The interobserver agreement was 0.41 (43). 
In a study done by Aoyoma et al, 37 cases of ASCUS were studied with histopathological 
and immunohistochemical follow up. The features taken into account were loss of 
polarity, absence of perinuclear halo, mitoses, presence of primitive cells in the upper 
two thirds and positivity for p16 and MIB-1 in the upper two thirds. 84.0% of neoplastic 
cases had 5 or more of these features. 89.0% of the non neoplastic cases had less than 2 
of these indicators (44). 
Once the use of Pap smear was established in detecting squamous lesions, attention was 
shifted towards detecting efficacy of pap testing for endocervical lesions. Another 
potentially troublesome and diagnostically challenging area for cytologists was “atypical 
squamous cells of undetermined significance”. This category caused a management 
dilemma for the clinicians as well. Therefore, a number of studies were done to improve 
the sensitivity of Pap tests. The next step was the advent of colposcopy. Colposcope is a 
binocular instrument that gives a 6 to 40 fold magnification. 4-5 % acetic acid is applied 
onto the cervix and acetowhite epithelium is assessed. The colour, contour, margins, 
iodine staining and arrangement of blood vessels are noted. Sharply delineated and 
opaque areas which persist for several minutes are characteristic of cervical 
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intraepithelial lesions and cervical carcinoma. It has been observed that glandular 
lesions cause more subtle changes. 
A study done in India observed that amongst cytology and visual inspection of cervix 
with acetic acid and Lugol’s iodine, cytology alone had a higher specificity and 
sensitivity. The sensitivity of visual inspection with acetic acetic acid, Lugols iodine and 
cytology were 64.5%, 64.5& and 67.7% respectively and specificity were 84.2%, 85.5% 
and 95.4% respectively. In addition, p16 positive CIN 3 (93.8%) and CIN 2 (76.9%) 
were positive on cytology as opposed to visual tests (68.8% and 53.8%) proving that 
cytology had a higher sensitivity to detect dysplasia of cervix  (45). 
In a study done by Phongnarison et al it was found that 36.4 % of women were 
diagnosed to have HSIL and 5 % had frank carcinoma when colposcopic biopsy was 
done following a diagnosis of LSIL. Hence the authors advise that in areas with high 
incidence of high grade squamous lesions, women with low grade lesions require an 
immediate colposcopic examination to rule out a higher grade lesion (46). A study done 
by Dolman et al also suggested that a repeat Pap smear done at the time of colposcopic 
examination is beneficial in women who have been diagnosed with high grade 
squamous lesions (47). 
A study was done in New York School of medicine to evaluate the significance of 
“endocervical crypt involvement” in HSIL. It was concluded that the diagnosis of 
endocervical gland involvement on Pap smears did not show increased frequency of 
glandular involvement on follow up biopsies (48). 
It is thought that the presence of endometrial cells in Pap smears of women above 40 
years of age is abnormal. However, a study done by Thrall et al showed that women 
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with endometrial cells in Pap smears did not have an increased incidence of 
endometrial hyperplasia or malignancies (49). 
Pap smear findings in cervical glandular lesions was extensively studied by Chengquan 
Zhao et al, 61.6 % had glandular cell lesions as the most common recent abnormal Pap 
smear finding. 38.4% had squamous cell abnormalities alone and 60% had coexisting 
cervical intraepithelial squamous neoplasia. 61.4% had a negative earlier Pap test taken 
within 4 months to 3 years. 97.2 % of the cases tested positive for Human Papilloma 
Virus (50). 
The rate of false positive histology according to colposcopic referral was studied by 
Palma et al. All CIN 1 and CIN 2 cases were blindly reviewed by two pathologists. The 
specificity and sensitivity of colposcopy guided biopsy were 98 % and 84 % 
respectively. Unnecessary treatment was given for 27% of women who had ASCUS, 8 % 
of women with LSIL and 10% of women who were HPV positive with cytological lesions 
in Pap test. (Any patient whose diagnosis was downgraded to a low grade lesion on 
biopsy was considered to have received unnecessary treatment) (51). 
The variable sensitivity and specificity for Pap smear as well as subjectivity of 
evaluation thus leading to a high rate of unnecessary treatment lead to the quest for a 
surrogate marker for a more objective evaluation. Duncan et al studied the use of p16 as 
a diagnostic aid in cases of ASCUS on Pap smear.p16 immunohistochemical stain was 
performed on Thin Prep smears diagnosed as ASCUS by 5 cytopathologists. It was 
followed up with tissue diagnosis, repeat smears and hybrid capture 2. It was 
demonstrated that p16 scores had a better correlation with tissue follow up than hybrid 
capture 2. The positive predictive value and sensitivity of p16, compared to tissue 
follow up were statistically more favourable. However, p16 expression was consistently 
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present in atrophic Pap smears, thus limiting its use alone in triage of atypical atrophic 
smears (52).  
It has been commonly observed that discordance exists between cervical punch 
biopsies, Pap smears and conisation specimens. The most common diagnostic error that 
has been noticed is the absence of dysplasia in conisation specimens when dysplasia has 
been reported in biopsies. Carrigg et al studied 53 negative conisation specimens with 
review of their prior biopsy and cytology.p16 immunohistochemical stain was 
performed on all the specimens. 26 % of conisation specimens were detected to have 
dysplastic lesions. 28 % of them were true negatives and the previous biopsies had 
overdiagnosed HSIL. However, 45 % of cones were actually negative but had HSIL in the 
pre surgical material. Amongst these 11 % showed evidence of dysplasia in subsequent 
biopsies and 26 % were negative on follow up. It was concluded that to prevent over 
diagnosis of HSIL on Pap smears and cervical biopsies, deeper level examination and 
use of p16 immunostain may be helpful. The causes for this discrepancy were thought 
to be sampling error, interpretation error, incomplete tissue examination, spontaneous 
regression of lesion and probably complete excision of a small focus of HSIL (53). 
Various studies have been done in different parts of the world to investigate the role of 
p16 as a surrogate marker in detecting cervical dyskaryosis. The diagnostic accuracy of 
p16 alone and in conjunction with other markers in cervical lesions has been 
extensively studied on Pap smears and cervical biopsy specimens for intraepithelial and 
invasive squamous lesions and glandular lesions.  
The ability of p16 to discriminate between CIN 1 lesions and non neoplastic equivocal 
epithelial lesions of cervix was studied by comparing 81 cases of CIN 1 with 52 cases of 
squamous metaplasia, 33 cases with HPV related cellular changes, 4 cases of 
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microglandular hyperplasia and 12 cases of chronic cervicitis. It was observed that none 
of the reactive conditions demonstrated positivity for p16. 19 cases of CIN 1 showed 
strong positivity and 4 cases showed focal positivity for p16. Of the remaining 58 CIN 1 
cases, 50 cases did not stain with p16 and were negative for HPV DNA on PCR (54). 
Yoshida et al in 2004 studied the usefulness of p16 expression in liquid based cervical 
smears and tissue sections and correlation with HPV DNA status. A total of 98 cases 
were studied, of which 38 cases were ASCUS, 12 cases LSIL, 33 cases HSIL and 15 cases 
frank carcinoma. It was found that the rate of concordance between cytological and 
histological diagnosis was higher in high grade dysplastic lesions than low grade 
lesions. 16 cases showed marked discordance between cytological and histological 
diagnosis. Diffuse and strong staining was observed in all HSIL and invasive carcinoma 
cases. Only two adenocarcinoma cases were negative for p16. 60 cases demonstrated 
positivity for high risk HPV and 55 cases out of 60 showed strong p16 positivity (55). 
Sano et al studied the expression pattern of p16 and retinoblastoma protein in cervical 
intraepithelial lesions as both the proteins are important components of cell cycle 
regulation. Out of 98 cases of cervical dysplastic lesions studied, all the cases showed 
strong nuclear and cytoplasmic positivity for p16. Scattered nuclei of normal as well as 
neoplastic cells showed Rb protein expression. Therefore, the study suggests that 
combined mutational inactivity or deletion of Rb and p16 proteins is unusual (56).  
A recent study published in May 2014 by Burgeron et al reinforces the advantage of p16 
immunohistochemistry over Pap smear testing which has low sensitivity and HPV 
testing which has a low specificity. The sensitivity and specificity of p16 cytology in 
ASCUS were found to be 92.6 % and 63.2 % respectively. When used in combination 
with MIB-1 proliferation index, the specificity increased to 80.6 %. However, the 
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sensitivity of HPV DNA was found to be 90.1 % and the specificity was 37.8 %. This 
proves the fact that all HPV colonised epithelial cells do not necessarily undergo 
neoplastic transformation. Therefore the study suggests that use of p16 alone has 
reasonably high sensitivity and specificity and can be used as a screening tool (57). 
p16 expression was evaluated in Thin Prep smears and cervical biopsy samples along 
with HPV detection and typing by Murphy et al. p16 expression was found to be 
negative in all normal cases. It was positive in all dysplastic glandular and squamous 
lesions, except one CIN 3 case. The staining pattern was predominantly nuclear in CIN 1 
cases, whereas both nuclear and cytoplasmic in CIN 2, CIN 3, cGIN and invasive 
carcinomas. All cases that were positive for HPV DNA showed a diffuse and strong 
staining for p16, however, all cases which showed p16 positivity were not positive for 
HPV DNA, thereby suggesting that other oncogenic pathways play a role in cervical 
neoplasia. p16 intensity was lower in cervical tissue harbouring low risk HPV. 10 % of 
normal cervical epithelium showed positivity for low risk HPV (HPV 6/11). HPV 16 was 
positive in all cases of cGIN. 72% if CIN 1 and 78 % each of CIN 2 and CIN 3 were 
positive for HPV 16. HPV 18 was positive in 4% of CIN 2 and 10 % of CIN 3. All the 
invasive carcinomas were positive for HPV 16. Thus HPV 16 was found to be the most 
prevalent oncogenic strain (58). 
The major drawback of interpretation of cervical dysplasia is the lack of interobserver 
agreement. It is also possible that a small focus of dysplasia in otherwise reactive 
epithelium maybe missed even by an experienced pathologist. A study done by Klaes et 
al assessed the difference in interobserver agreement in Haematoxylin and eosin 
stained sections and immunohistochemical stain for p16 using kappa statistics. The 
opinions of five experienced pathologists were sought. It was found that significant 
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discordance exists between interpretations of tissue sections which were particularly 
high in case of low grade lesions (kappa value 0. 60). However, the agreement was 
better in interpreting p16 expression (kappa value 0. 91). It was also observed that p16 
expression was limited to dysplastic epithelium in CIN 1, 2 and 3 lesions clearly 
delineating adjacent reactive epithelium and thus enabling the pathologist to detect 
even a small focus (4). 
A study done by Karcheva et al divided the cervical lesions into 4 categories: non 
dysplastic lesions which include immature squamous metaplasia, atypical squamous 
metaplasia, inflammation and inflammatory atypia., increasing grades of cervical 
intraepithelial neoplasia, invasive squamous cell carcinoma and glandular lesions 
including microglandular hyperplasia, endocervical dysplasia and adenocarcinoma. 
There was statistically significant association between p16 expression and dysplastic 
lesions. None of the reactive lesions stained positive for p16, thus making it an 
independent and reliable marker for cervical dyskaryosis (59).   
A systematic review done by Tsoumpu et al established the use of p16 as an adjunct 
marker for cervical dysplasia in cytological and tissue specimens. It was observed that 
the proportion of cervical Pap smears expressing p16 increased with increasing severity 
of dysplasia. 12 % of the normal smears, 45 % of ASCUS and LSIL and 89 % of HSIL 
cases showed diffuse and strong positivity for p16. In tissue sections, 2% of normal 
biopsies, 38 % of CIN 1, 38 % of CIN 2 and 82 % of CIN 3 showed strong expression(60). 
Another study done in Germany investigated the accuracy of p16 in detecting high 
grade lesions on 500 tissue sections of cervical punch biopsies and conisation 
specimens. Dichotomised gold standard was established by consensus of 3 expert 
cytopathologists. There was a significant improvement in diagnostic accuracy when p16 
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immunostain was added (p value = 0.0004). The sensitivity to detect high grade lesions 
increased by approximately 13 %. False negative results were reduced by half. There 
was significant increase in the interobserver agreement which increased from 0.566 to 
0.749 (p value = 0.001).  There was excellent reproducibility as well (kappa value = 
0.899). Thus the study concluded that the use of p16 would aid as a diagnostic tool in 
detecting cervical dysplasia due to improved interobserver agreement(61). 
A tissue microarray study on 796 specimens was done by Lesnikova et al. Tissue 
microarray is a technology used to study gene expression in tissue sections. Small cores 
of tissue are removed from the paraffin blocks and arrayed. Multiple samples can be 
stained simultaneously for a single biomarker or immunohistochemical stain. One 
advantage of this study was that all samples undergo staining with same protocol thus 
ensuring uniformity. Two methods of analysis were used: (1) Simple method – 
evaluated as positive or negative. (2) Semi quantitative method- Scoring system based 
on intensity and proportion of staining. Normal cervical tissue did not stain for p16. 
However, 72.3 % of CIN 1, 91.0 % of CIN 2, 98.3 % of CIN 3 and 98.5 % of invasive 
carcinomas showed positivity for p16. Both the scoring systems were compared. The 
semi quantitative system gave a detailed account of the spread of dysplasia, however 
overall performance of both the systems was comparable. It is known that many of the 
low grade lesions undergo spontaneous regression. Since transcription of E7 protein of 
HPV is required for upregulation of p16, it was suggested that low grade lesions 
expressing p16 are more likely to undergo transformation into high grade lesions (3). 
Diagnostic value of p16 in preneoplastic and neoplastic lesions of squamous and 
glandular epithelium was studied by Izadi Mood et al. 81.8 % of low grade CINs, 91 % of 
high grade CINs, 90 % of squamous cell carcinomas and 75 % of adenocarcinoma 
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strongly expressed p16 protein. 10 % of normal cervical tissue showed p16 positivity. 
When the relationship between reaction intensity and lesion severity was compared, 
both were found to be significantly different in different histological subtypes. However, 
reaction intensity was proved to be superior in logistic regression model, thus making it 
the best parameter to assess p16 expression (p value < 0.005) (62). 
The expression pattern of p16, MIB-1 and HPV viral load were used to predict residual 
disease in conisation specimens with positive margins. The expression of p16 and     
MIB-1 had significant association with grade of CIN (p values = 0.0012 and 0.0006 
respectively). In both univariate and logistic regression analysis, the following 
parameters did not have significant association with residual disease after conisation 
with positive margins: Age, parity, cytology, grade of the lesion, load of HPV and 
expression of p16 and MIB-1 (p value > 0.05). However, HPV viral load showed 
significant differences with expression of p16 and MIB-1  (63). 
A study done in Gunma University, Japan, tried to use p16 expression pattern to 
differentiate between premalignant and malignant lesions of cervix and condyloma 
acuminatum, which is a benign HPV induced change in cervical epithelium. Correlation 
with HPV subtyping was also done. It was found that there was diffuse and strong 
positivity for p16 in high grade premalignant and malignant lesions caused due to high 
and intermediated grade HPV, namely HPV 16, 18, 31, 33, 52 and 58. Low grade lesions 
and Condyloma acuminata showed absent or weak staining. This is thought to be due to 
difference in functional inactivation of retinoblastoma protein by different strains of 
viruses. Thus, it enables the distinction between low grade and high grade HPV 
infections (64). 
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Once the role of p16 in squamous lesions was established, focus was shifted to glandular 
lesions. The emphasis on glandular lesions also increased as a wider spectrum of 
endocervical lesions were described by McCluggage. He put forward that a spectrum of 
benign, premalignant and malignant lesions exist in the glandular compartment. The 
role of HPV in neoplastic progression was also increasingly becoming clearer. Relatively 
newer entities were also described which pose a diagnostic challenge to the pathologist 
such as typical and atypical lobular endocervical glandular hyperplasia, tunnel clusters, 
adenoma malignum and adenocarcinoma, gastric type. It was also pointed out that 
tubulosquamous polyp, derived from paraurethral Skene’s glands can also mimic a low 
grade adenocarcinoma. Even though adenocarcinoma in general has a poorer prognosis 
compared to squamous cell carcinoma, evidence suggests that early adenocarcinoma 
has a comparatively better prognosis and is amenable to conservative management. 
Since it is essential to establish the site of primary tumour, it was imperative to have a 
marker which gives reasonably high sensitivity and specificity to establish cervical 
origin. The conventional panel of markers, namely, estrogen and progesterone 
receptors, CEA and Vimentin had their pitfalls especially in case of low grade 
adenocarcinoma. It was also noted that there is increasing frequency of association 
between cervical neuroendocrine neoplasias and glandular neoplasias(65). Colposcopy 
was also not as effective in detecting glandular lesions compared to squamous lesions. 
The expression profile of p16 was studied in adenocarcinoma and its precursors and 
benign lesions of endocervical glands by Negri et al in 2003 in tissue sections and Thin 
Prep smears. HPV DNA detection was done using Hybrid capture 2. A total of 45 cases 
were studied: 18 invasive, 8 adenocarcinoma in situ, 4 atypical glandular lesions and 15 
reactive conditions of endocervix. All cases of invasive as well as in situ adenocarcinoma 
demonstrated strong and diffuse positivity for p16. Four cases of atypical glandular 
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lesions showed only focal expression. All reactive conditions showed negative staining. 
In Thin Prep smears, all neoplastic endocervical cells showed strong positivity. All the 
high grade lesions and carcinoma were associated with high grade HPV (66). 
Concomitant p16 expression along with MIB-1 proliferation index and HPV detection 
was used to distinguish between reactive glandular lesions and early endocervical 
glandular neoplasia. It was found that strong and diffuse expression of p16 along with 
moderate to high MIB-1 proliferation index was observed in cases of adenocarcinoma in 
situ. All the cases were positive for high risk HPV as well. However, a weak staining for 
p16 was observed in endometrial epithelium and tubo-endometrial metaplasia. They 
were negative for high risk HPV and had a low MIB-1 index. Thus, the authors suggest 
the use of MIB-1 and high risk HPV detection in ambiguous cases (67). 
A study from Netherlands done by Zeilinski et al used a combination p53 and p16 with 
high risk HPV detection. Atypical glandular lesions are not as frequently diagnosed as 
squamous lesions in Pap smears. Moreover, it is diagnostically challenging to 
distinguish endocervical adenocarcinoma from endometrial carcinomas. It was 
proposed that incorporating immunohistochemical markers and high risk HPV testing 
may improve the detection rate of atypical glandular lesions in screening programmes. 
65 cases of adenocarcinoma in situ and 77 cases of adenocarcinoma were studied. High 
risk HPV was detected in all cases of in situ carcinomas and 94 % cases of cervical 
adenocarcinoma. None of the 20 endometrial adenocarcinoma demonstrated HPV 
positivity. HPV 18 was the most prevalent subtype and was present in 55 % of cervical 
adenocarcinoma and 68 % of in situ carcinomas. Strong and diffuse staining for p16 was 
noted in 95 % of high risk HPV positive adenocarcinoma (p value <0.001). Significant 
association was present between p53 immunostaining which marks stabilised wild type 
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or mutant p53 protein and high risk HPV. However, there was no difference in staining 
pattern of p53 and p16 in HPV negative adenocarcinoma and endometrial 
adenocarcinoma. As only a very few cases of cervical adenocarcinoma were negative for 
HPV, it was suggested that p16 immunostaining would be a useful marker to establish a 
primary endocervical adenocarcinoma (68). 
HPV detection pattern and p16 expression were studied in unusual variants of 
adenocarcinoma and compared with usual type by Houghton et al. A total of 63 cases 
were studied which included 43 usual type, 3 gastric type, 3 intestinal type, 4 clear cell 
type, 3 mesonephric type, 2 serous type, 1 hepatoid type and 4 minimal deviation type. 
All cases underwent immunohistochemical staining with p16 and HPV genotyping. 57 % 
of all cases showed HPV positivity. The commonest subtypes were HPV 16 and 18. All 
cases of usual type and single serous carcinoma were positive for HPV.  Rest of the 
unusual type cases were negative for HPV.  42 out of 43 usual type cases showed strong 
and diffuse positivity for p16. 2 out of 4 minimal deviation type, 2 out of 3 gastric type 
and 1 out of 2 serous carcinoma showed strong p16 staining. 1 out of 3 intestinal type, 2 
out of 3 mesonephric type and 1 out of 4 clear cell type showed focal p16 staining. Thus 
it was concluded that p16 positivity in unusual subtypes in the absence of high risk HPV 
is attributed to retinoblastoma inactivation by some mechanism other than HPV (69). 
p16 expression was used to discriminate between adenocarcinoma of endocervical and 
endometrial origin. p16 immunohistochemical stain along with HPV DNA detection was 
done in 24 cases of endometrial and 19 cases of endocervical adenocarcinoma. p16 was 
strongly expressed in 18 endocervical adenocarcinoma cases, out of which 14 were 
positive for HPV DNA. In contrast, endometrial carcinomas showed a patchy and weaker 
staining for p16 and all the cases were negative for HPV DNA (5). 
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A number of studies were done in various centres in India to assess demographic 
difference in HPV prevalence and p16 expression in cervical dysplastic lesions. A study 
done by Tripathi et al in 2003 documented various genetic alterations in p16 locus in  
women with cervical dysplasia. It was found that 15 out of 46 cases (33 %) showed 
alterations in p16 gene. Mutations were present in 7 out of 46 cases (15 %). Most of the 
mutations occurred in exon 2, one mutation at intron 1 / exon 2 splice junction and 
three were silent mutations. Homozygous deletion and promoter hypermethylation 
were detected in 4 out of 46 cases (8.7 %) and 3 out of 46 cases (6.5 %) cases 
respectively. Microsatellite size changes and loss of heterozygozity were detected in 8 
out of 46 (17 %) of samples. It was also found that high risk HPV (HPV 16/18) was 
present in 35 out of 46 (76 %) samples. There was no significant association between 
HPV infection and p16 alterations (70). 
Another study done in PGIMER, Chandigarh assessed p16 expression in 20 cases each of 
normal cervical epithelium, CIN 1, CIN 2, CIN 3 and invasive carcinomas. It was found 
that 18 out of 20 normal cases were negative for p16. Only 20 % of CIN 1 cases showed 
p16 positivity. 45 %, 55% and 95 % of CIN 2, CIN 3 and invasive carcinomas showed 
p16 positivity. The statistical difference between p16 expression patterns was found to 
be significant between CIN 2, CIN 3 and invasive carcinomas. (p values = 0.021, 0.008 
and 0.000 respectively) (71). 
A study done in Regional Cancer Centre, Thiruvananthapuram, assessed the association 
between p16 expression in cervical neoplasia and presence of HPV DNA in southern 
India. A total of 177 cases were studied out of which 42 were classified as benign, 34 as 
LSIL, 48 as HSIL and 53 as invasive carcinoma.  32 out of 42 benign cases were negative 
for p16. In LSIL category, 28 out of 34 cases were positive for p16 protein. 45 out of 48 
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cases of HSIL and 50 out of 53 invasive carcinomas showed strong diffuse staining 
pattern. HPV DNA was absent in all the benign lesions. HPV DNA was detected in 47 
cases, of invasive carcinoma, 37 HSIL and 3 LSIL samples. Of these, high risk subtypes, 
HPV 16/18 were found in 37 HSIL and 42 carcinoma cases. Low risk subtypes, HPV 
6/11 were found in 3 LSIL and 1 carcinoma samples. 1 carcinoma case was positive for 
HPV 31/33/35. HPV was not detected in any of the benign lesions. 41 cases were 
negative for both HPV DNA and p16 protein. 96 cases expressed strong p16 staining out 
of which 73 were positive for high risk HPV. The samples positive for low risk subtypes 
showed sporadic p16 positivity and belonged to LSIL category. Thus a statistically 
significant association (p value <0.001) exists between high risk HPV and strong p16 
expression (72). 
The usefulness of combination of p16 expression and MIB-1 proliferation index in 
detecting cervical neoplasias was studied by Srivastava et al in 2013. p16 expression 
was absent in all benign lesions and MIB-1 proliferation was restricted to basal one 
third. Strong p16 expression was detected in 8/10 LSIL/CIN 1 cases, 5/5 HSIL/CIN 2 
cases, 3/3 HSIL/CIN 3 and 15/15 squamous cell carcinoma cases. Increased MIB-1 
proliferation index was detected in 14 out of 15 cases of CIN 1 and all the cases of CIN 2, 
CIN 3 and invasive carcinomas. Thus it was concluded that with increasing severity of 
cervical dysplasia, there was consistently strong staining of p16 and increasing MIB-1 
proliferation index (73). 
Once the use of p16 as a diagnostic marker was indisputably established, its role in 
prognostication and management was investigated. Promising biomarkers have 
emerged that are associated with E6 and E7 viral proteins. A study done by Pacchiarotti 
et al, used p16 for prognostication of cases with HPV positivity or positive cytology but 
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absent high grade dysplasia (above CIN 2). All cases negative for malignancy and CIN 1 
histology were followed up for 6 to 12 months with colposcopy or cytology. 83.5 % of 
the patients had at least one follow up. 30.6 % were CIN 1 cases, 67.2 % were negative 
for intraepithelial lesion and 2.2 % were inadequate histology. 79.4 % of all cases were 
negative for p16 staining, 17.3 % were positive for p16 and 3.2 % cases were invalid. 
During follow up 10 cases progressed to CIN 2 and 3 cases to CIN 3, out of which 6 cases 
were positive for p16 (sensitivity 46 %). There was a significant difference in absolute 
risk among p16 positive women (9.4/100) compared to p16 negative cases (1.7/100). 
CIN 1 cases had a higher risk compared to histologically negative patients (relative risk 
5.2). Thus it was confirmed that p16 is a reliable prognostic marker for follow up after a 
negative colposcopy (74).  
However, there was a contradictory study which stated that p16 expression was unable 
to predict the outcome of cervical intraepithelial neoplasia grade 2. Ninety women were 
diagnosed to have high risk HPV and CIN 2 out of which 45 women underwent excision 
and 45 women were followed up for 1 year at 3 months interval. p16 expression was 
analysed in all cases and 68.9 % of the cases showed positivity. 22 % showed 
progression to CIN 3, in 11 % of women, the lesion persisted, 42 % had spontaneous 
regression and the lesion was downgraded to CIN 1 in 11 %. There was no significant 
difference in regression between women who were p16 positive and negative (adjusted 
HR 1.1). Since rate of spontaneous regression was high, the authors advise follow up as 
a management option in compliant women(75). 
The role of p16 as predictive marker in lymph node metastasis was studied by Huang et 
al. Of the 145 cases of invasive squamous and adenocarcinoma studied, 32.4 % showed 
strong expression, 42.1 % showed moderate staining and 25.5 % showed weak or 
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absent expression for p16. Over expression of p16 demonstrated significant association 
with histological cell type (Squamous > Adenocarcinoma) (p value = 0.015), FIGO 
staging (p value = 0.041) and lymph node metastasis (p value = 0.005). However, there 
was no significant association with grade, lymphovascular invasion, parametrial 
invasion, tumour size, depth of stromal invasion and vaginal invasion. The 5 year 
survival rate was 65.5 %. Kaplan Meier curve demonstrated that p16 over expression 
was associated with a poorer survival compared to p16 underexpression (59.3% vs. 
83.8%). The mean survival of women with p16 under expression was 171.6 months and 
that of women with p16 over expression was 130.0 months. In addition to p16 
expression, other factors associated with poor survival were advance FIGO stage, 
tumour size, vaginal involvement, lymphovascular and parametrial invasion and nodal 
metastasis (6). 
The presence of p16 negative high grade cervical lesions and carcinomas was pointed 
out by Volgareva et al. 62.7 %, 68.4 %, 33.3 % and 3.8 % of CIN 1, CIN 2, CIN 3 and 
invasive carcinomas were negative for p16. 10 % of cases with only koilocytic change 
showed p16 positivity. The authors suggested that epigenetic mechanisms like loss of 
heterozygosity and promoter hypermethylation that cause silencing of p16 is the 
probable cause for absent or reduced expression of p16 (76).   
As a small subset of cervical cancers is negative for high risk HPV, studies were done to 
differentiate the genetic profile of HPV positive and HPV negative cervical cancers. It 
was observed that HPV positive cervical cancers over express cyclin E, cyclin B and p16 
and under express cyclin D1. Down regulation of p16 in HPV negative cancers 
correlated with p16 promoter hypermethylation and cyclin D1 repression linked with 
gene amplification (77). 
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 After establishing that p16 can be used for diagnostic and prognostic purpose, various 
studies were done using a combination of several markers so as to develop a reliable 
panel with a sufficiently high sensitivity and specificity, which can establish cervical 
primary lesion and has a good interobserver agreement. The immunocytochemical 
staining pattern of a panel of markers comprising p16, PTEN, p53, FAS and HPV capsid 
protein on Thin Prep smears were studied. A total of 92 cases were evaluated. p53 was 
detected in 36.4 % of HSIL cases and were absent in normal and LSIL cases. PTEN 
positivity was observed in 97.8 % of all cases and 81.8 % of HSIL. Fas was expressed by 
96.7 % of all cases and 72.7 % of HSIL. Positive expression of L1 protein and p16 was 
observed in 26.3 % of LSIL and 9.1 % of HSIL cases. p16 positivity with negative L1 was 
present in 18 % of LSIL and 81.8 % of HSIL. p16 negativity and L1 positivity was found 
in 5 % of normal cases, 42.6 % of LSIL, negativity for p16 and L1 was observed in 9.1 % 
of HSIL, 13.1 % of LSIL and 95 % of normal cases. It was found that p16 positive/L1 
negative and p16 negative /L1 negative had significant association with HSIL and LSIL 
respectively (p value <0.001). None of the other markers had significant prognostic 
value in LSIL cases. Thus the authors suggest that loss of Fas and PTEN along with over 
expression of p53 may be used in detecting high grade lesions  (78). 
Another study was performed by combining p16, MIB-1 and HPV L1 capsid protein on 
cell blocks of residual liquid based cytology specimens. A total of 42 specimens were 
studied with follow up. There was 90.5 % concordance between cytology and histology. 
There was statistically significant difference between the expression patterns with 
increasing severity of dysplasia. The rate of positive staining of p16 in normal, CIN 1, 
CIN 2/3 and carcinoma were 0 %, 40 %, 100 % and 100 % respectively. MIB- 1 also 
showed a similar staining pattern of 0 %, 40 %, 87 % and 100 %. Since many of low 
grade lesions undergo spontaneous regression, attempts were made to predict which of 
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the cases are likely to upgrade into a more severe lesion. This study also demonstrated 
that those cases with both p16 positivity and L1 capsid positivity are likely to undergo 
neoplastic transformation (79). 
It is known that CDKN2 encodes for p16 which is dependent on retinoblastoma pathway 
and p14 ARF blocks MDM2 mediated degradation of p53. 65 samples were analysed 
using a panel of markers, p16, p53, p14 AFR and MDM2. Over expression of MDM2 was 
detected in 75 % of condylomas and 16 % of dysplasias, thus making it a useful 
discriminatory marker between benign and malignant conditions. All the cases 
including carcinomas and reactive cases showed a weak positivity for p53, thus it was 
concluded that it was not useful in discriminating reactive and malignant conditions. 
p14 ARF was over expressed in all carcinoma cases, even in HPV negative carcinomas 
and were negative in all benign lesions. p16 was over expressed in all cases of 
carcinomas and there was a statistically significant difference in expression between 
various grades of dysplasia (80). 
11850 cervical biopsy samples were analysed by 23 pathologists in a study done by 
Singh et al. An average of 518 cases was seen by a pathologist over 5 years. 12 
pathologists were “low users” and 11 pathologists were “high users” of p16 
immunohistochemical stain. When both the sets were compared, it was found that “high 
users” had a lower rate of discrepancies between cytology and histology (12.6 % vs. 
14.92 %), greater rate of diagnosis of CIN 2 (19.9% vs. 16.4 %) and lower CIN 1/ CIN 2 
ratio. (1.2 vs. 2.3) (81). 
Another panel of markers, excluding p16 were used; MIB-1, c-erb2 and cyclin D were 
used in CIN 1, CIN 2, CIN 3 and squamous cell carcinomas. High risk HPV was detected 
in 82% of LSIL, 89 % of HSIL and 100 % of carcinomas. 9%, 33 % and 50 % of LSIL, HSIL 
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and carcinomas showed positivity for c-erb2. Nuclear expression of cyclin D1 was 
present in 82 %, 11 % and 30 % of CIN1, CIN 2 and squamous cell carcinoma cases 
respectively. It was observed that cytoplasmic cyclin D1 expression increased with 
increasing severity of lesion. The presence of both nuclear and cytoplasmic cyclin D1 
positivity was related to high risk HPV infection (82). 
Evaluation of expression pattern of p16 and MIB-1 was done in cervical cone biopsies. 
Diffuse expression of p16 was detected in 57.1 % of CIN 1, 73.9 % of CIN 2 cases and 
100 % of CIN 3 and carcinoma cases. MIB-1 was coexpressed in the same cells that 
showed strong and diffuse positivity for p16. Thus, the study reflects that p16 is a 
marker for proliferation competent cells (83). 
When ProExC was combined with p16 for detecting cervical dysplastic lesions, it was 
found that p16 had a superior sensitivity for CIN 2 and CIN 3 lesions (79% and 90%) 
compared to ProExC which had a sensitivity of 67 % and 84 % respectively for CIN 2 
and CIN 3. However, in terms of specificity ProExC was superior with 100 % specificity 
for CIN 2 and 93 % for CIN 3. But taking into account cost effectiveness, p16 had a better 
overall performance as a marker for dysplasia than ProExC (84). 
Another study included cyclin E to the panel of p16 and MIB-1. Histological diagnosis 
had a significant correlation with all the three markers (p value <0.01). MIB-1, Cyclin E 
and p16 had positive scores of 94.7%, 91.6% and 100 % respectively in cases of HSIL 
and 68.4 %, 96.7% and 100 % in cases of LSIL. Cyclin E and p16 were equally sensitive 
to detect high grade and low grade intraepithelial lesions. Reactive epithelial cells had a 
score of 7.7 %, 8.0 % and 12 % respectively for the three markers (85). 
Histologically, adenocarcinoma poses a greater diagnostic challenge and usually 
requires a panel of markers. p21 expression along with p16, cyclin E and p27 were 
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analysed. There was significant correlation between the expression of p16 and p27, 
cyclin E and p27, and cyclin E and p21. Negative staining for p21 was also associated 
with an overall poor survival (86). 
A study done by Cameron et al used a panel of p16, MIB-1 and bcl-2 to differentiate 
between glandular neoplasia and benign conditions like endometriosis, endometrial 
metaplasia and microglandular hyperplasia. Cases of glandular neoplasia showed strong 
positivity for p16 with high MIB-1 proliferation index and a negative staining for bcl-2. 
Endometriosis and endometrial metaplasia showed strong bcl-2 positivity, focal p16 
positivity and low MIB-1 proliferation index. Microglandular hyperplasia demonstrated 
negativity for bcl-2 and p16 along with low MIB-1. Thus, the panel was successful in 
discriminating the reactive and neoplastic lesions(87). 
Role of p16 has been investigated in other tumours and was observed that high grade 
serous ovarian carcinomas had a significantly stronger expression of p16 compared to 
low grade and borderline tumours. (88). The role of p16 and association of HPV have 
been extensively studied in orpharyngeal carcinomas and p16 emerged as the strongest 
independent predictor of prognosis, even more than tumour size, stage and nodal 
status(89). 
To conclude, various studies have proven that p16 is a reliable surrogate marker for 
cervical dysplasia in terms of sensitivity, specificity, discriminatory ability and cost 
effectiveness. p16 has also been used as a prognostic marker to determine overall 
survival and disease free survival.  
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AIM 
 
 
To study the p16 expression pattern in premalignant and malignant lesions of 
cervix in biopsy specimens. 
 
 
OBJECTIVES 
 
 
a. To evaluate the diagnostic utility of p16 to differentiate between the 
premalignant and malignant squamous and glandular lesions of cervix. 
b. To assess the utility of p16 to distinguish between benign and dysplastic 
lesions of cervix. 
c. To assess the clinical impact of p16 expression on the disease outcome. 
d. To assess the performance of cytology as a screening tool compared to 
histology. 
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MATERIALS AND METHODS 
 
All the procedures involved in the study were approved by the Institutional Review 
Board of Christian Medical College, Vellore. Cervical biopsy samples received in the 
department of General Pathology, Christian Medical College, Vellore, from 1st June 2011 
to 31st May 2013 were utilised for the study. The study was retrospective and archival 
stained and mounted slides and formalin fixed paraffin embedded tissue blocks were 
retrieved. The samples had been fixed overnight in 10% buffered formalin and were 
embedded in paraffin wax using conventional methods. Haematoxylin and eosin stained 
slides of all cases of cervical biopsy were reviewed. 
Strict histomorphological criteria were used to classify all the cases into four distinct 
categories:  
1st category – All reactive non dysplastic conditions which mainly include infections, 
inflammation, regenerative changes, hyperplasia, endometriosis, post radiation changes 
endocervical polyps, koilocytosis and metaplasias. 
2nd category – Different levels of dysplasia, i.e., premalignant lesions of cervix, Cervical 
Intraepithelial Neoplasia, grades 1, 2 and 3(CIN 1, 2 and 3). 
3rd category – Invasive squamous cell carcinomas. 
4thcategory–Microglandular hyperplasia, adenocarcinoma in situ and invasive 
adenocarcinoma. 
Clinical and radiological data were obtained from clinical workstation and the initial 
pathological diagnosis was reviewed from Pathology workstation using PACS (Picture 
Archival and Communication System).  
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The clinical parameters evaluated were age at the time of diagnosis, mode of 
presentation, relevant history, cytological diagnosis, details of other related procedures 
like colposcopy and presence of iodine acetowhite areas, appearance of cervix during 
clinical examination, evaluation of uterus and adnexal structures. In case of 
malignancies, radiological staging, lymph node metastasis, invasion into pelvic 
structures, and distant metastasis were also noted. Previous biopsies and follow up 
biopsies and Pap smears were also evaluated to assess disease progression. 
CRITERIA FOR DIAGNOSIS 
Criteria for diagnosis for CIN 
 
Nuclear abnormalities  
 (1) Increased nucleo-cytoplasmic ratio due to disproportionate nuclear enlargement  
(2) Presence of hyperchromasia and irregular clumping of chromatin  
 (3) Anisokaryosis and pleomorphism of nuclei 
 (4) Loss of nuclear polarity  
(5) Irregular nuclear membrane. 
 Nuclear atypia of premalignant lesions is distinguished from the nuclear atypia of 
reactive changes by the heterogeneity of nuclear changes in premalignant conditions, in 
contrast to relatively homogenous changes in atypia of reactive conditions. Nucleoli are 
relatively rare in premalignant conditions. 
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Mitotic activity  
 
(1) Number of mitotic figures was counted in 10 high power fields (40 X magnification).  
(2) Location of mitotic figures – lower, middle or upper one third of the epithelium.  
(3) Presence of abnormal configurations. 
 It is described as  
Lag type mitosis - non attached chromatin in metaphase in the area of mitotic figure. 
Three group metaphase – the main bulk of chromatin aligns along the equator and non 
attached chromatin lies laterally at the two polar sites.  
Two group metaphase – displaced chromatin is present only in one pole.  
Other less common forms are multipolar tripolar and bizarre mitotic figures. 
Differentiation 
 
 Proportion of epithelium showing differentiation – basal one third, two third or full 
thickness dysplasia. 
Criteria for diagnosis of squamous cell carcinoma   
 
Nuclear and cytological abnormalities mentioned above along with 
 (1) Stromal invasion; extent of invasion – less than 3mm invasion into stroma is termed 
microinvasive carcinoma. Any macroscopically visible tumour or tumour with more 
than 3mm of stromal invasion is considered invasive carcinoma. 
 (2) Presence of stromal desmoplasia and necrosis 
 (3) Grade of differentiation –  
Well differentiated (grade 1): mature squamous cells with the presence of abundant 
keratin including formation of keratin pearls and intercellular bridges. 
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Moderately differentiated (grade 2): Less abundant keratin with focal individual cell 
keratinisation, less well demarcated cell borders, higher mitotic activity and nuclear 
pleomorphism. 
Poorly differentiated (grade3): Sheets and nests of primitive cells with marked 
pleomorphism and high nuclear cytoplasmic ratio, presence of basaloid and spindle cell 
morphology or squamous differentiation made out only on immunohistochemistry. 
Criteria for diagnosis glandular neoplasia 
 
 (1) Presence of intracellular mucin 
 (2) Increased nucleo- cytoplasmic ratio 
 (3) Mitoses evaluated as above 
 (4) Apoptosis 
 (5) Nuclear pleomorphism 
 (6) Nuclear hyperchromasia 
 (7) Loss of nuclear polarity. 
Criteria for diagnosis of invasive adenocarcinoma  
 Above mentioned criteria with stromal invasion along with stromal desmoplasia or 
necrosis. 
Grade of differentiation – Well differentiated adenocarcinoma (grade 1): Presence of 
well formed glandular structures with easily demonstrable Periodic Acid Schiff positive 
mucin and less than 5% solid areas. 
Moderately differentiated adenocarcinoma (grade 2): Less conspicuous glandular 
architecture with less amounts of mucin and 5 to 50% solid areas. 
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Poorly differentiated adenocarcinoma (grade 3): Solid sheets of tumour amounting to 
more than 50% with occasional pseudo rosettes and palisaded nuclei and little 
intracytoplasmic mucin.  
Endocervical origin of the tumours was confirmed by positive immunohistochemical 
expression for CEA and negative expression of Vimentin and ER. 
Criteria for diagnosis of reactive changes 
 
(1) Absence of features of CIN, glandular neoplasia or invasive malignancy. 
 (2) Predominance of inflammatory component.  
Criteria for diagnosis of koilocytes 
 
(1) Sharply defined perinuclear halo. 
(2)  Peripheral condensation of cytoplasm  
(3)  Nuclear size two to three times that of an intermediate cell or multinucleation  
(4)  Wrinkling of nuclear membrane. 
A total of 284 cervical biopsy specimens were received, out of which 53 were        
excluded due to inadequate tissue, presence of erroneous tissue (mainly endometrial 
samples), non availability of paraffin embedded blocks or scant tissue remaining in the 
block inadequate for immunohistochemistry, other morphological variants of cervical 
carcinoma and slide and block review. The remaining 231 cases were reviewed and a 
total of 120 cases which strictly obeyed the diagnostic criteria mentioned above for 
various categories were included in the study. 15 cases each of CIN 1, 2 and 3, 15 cases 
of invasive squamous cell carcinoma and 22 cases of adenocarcinoma and 38 cases of 
reactive condition were chosen.  The relatively higher number of preinvasive lesions 
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was included as they pose greater diagnostic challenge compared to frank invasive 
squamous cell carcinoma. 
Histology 
 
At least three H&E (Haematoxylin and eosin) stained sections of all 120 cases were 
reviewed by two pathologists. A consensus was reached and only the cases that strictly 
adhered to the diagnostic criteria were selected for the study. A CH-20i microscope 
(Olympus Corporation, Japan) was used for the study. 
 
 
                                       
 
 
 
 
 
 
 
 
Figure 4: Flow chart depicting the distribution of cases included in the study. 
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p16 INK4A immunohistochemistry was performed on 120 tissue biopsies. The antibody 
specifications are as follows: 
Manufacturer: CINtech, Ventana Medical Systems. 
Species: Mouse monoclonal 
Isotype: IgG2a 
Clone name: E6H4 
Catalogue number: 725 – 4713. 
Steps for immunohistochemistry  
 
(1) Tissue was fixed overnight in 10% buffered formalin. 
(2) Paraffin embedded tissue sections were cut at 5 micrometer thickness and floated 
onto poly L – lysine coated slides 
(3) Overnight incubation at 37 degree Celsius. 
(4) The slides were treated with 4% milk solution for 10 minutes to eliminate the 
hydrophobic effect and to give positive charge to the slides. 
(5) Slides were then bar-coded 
(6) Endogenous peroxidise blocking using 0.3% hydrogen peroxide for 10 minutes. 
(7) Immunohistochemistry was performed on the labelled slides using Ventana 
Benchmark XT autostainer (fully automated stainer). 
(8) Heat mediated antigen retrieval was done by treating with  standard cell 
conditioning 1 (CC1) solution (pH patent with company) for one hour at 90 degree 
Celsius. 
(9) Addition of primary antibody and incubation for 40 minutes at 37 degree Celsius. 
(10) Wash with reaction buffer  
(11) Addition of secondary antibody (multimer) and incubation for 8 minutes. 
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(12) Wash with reaction buffer 
(13)  Counter stain with Haematoxylin for 8 minutes. 
(14) Incubate with bluing agent for 4 minutes. 
(15) The slides were then brought to 80% alcohol (2 changes) to remove the liquid cover 
slip followed by drying and mounting in DPX. 
(16) Counter stain with copper haematoxylin (10%) and blue ink. 
A tissue section of invasive squamous cell carcinoma of cervix was taken as external 
positive control in each batch.  
Immunopositivity for p16 was evaluated using three parameters: 
A semi quantitative scoring system was done based on intensity and proportion of 
staining. 
Table 1: Scoring system for p16 used in this study 
INTENSITY PROPORTION PATTERN 
0  -  No staining 
1 – Weak staining 
2 – Moderate staining 
3 –Strong staining 
0 – No staining 
1 – Staining in < 1% of cells 
2 – Staining in 1 – 10 % of cells 
3 – Staining in 11 – 33 % of cells 
4 – Staining in 34 – 66 % of cells 
5 – Staining in > 66 % of cells 
N – Nuclear 
C – Cytoplasmic 
M - Membranous 
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Statistical Analysis 
Data was analysed using Statistical Package for Social Sciences (SPSS) software 
(Windows version 16). Descriptive statistics for continuous data was expressed as 
mean with S.D or median. Categorical data was expressed as frequencies and 
percentages.  Sensitivity and specificity of p16 expression in cervical dysplasia were 
obtained from ROC curves.  Association between koilocytosis and CIN was calculated 
using Fisher’s exact chi square test. Association between p16 expression and 
radiological parameters and tumour differentiation was calculated using non 
parametric Kruskal Wallis test. Correlation of intensity and proportion of p16 
expression with severity of lesion was obtained from Bland Altman plot. Time taken for 
progression of lesion was derived from Kaplan Meir curve.  For all statistical analysis,    
p value < 0.05 was considered significant. 
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RESULTS 
 
A total of 120 cervical biopsy samples were studied - 15 cases each of CIN 1, CIN 2, CIN 3 
and squamous cell carcinoma out of which 8 were poorly differentiated and 7 were 
moderately differentiated tumours. Of the remaining 60 cases, 38 were reactive and 
benign lesions of squamous and glandular compartments and 22 cases were 
adenocarcinoma out of which 7 were well differentiated, 13 moderately differentiated 
and 2 were poorly differentiated tumours. 
Table 2: Distribution of cases according to the diagnosis included in the study 
Cervical Intraepithelial Neoplasia 
CIN 1 
CIN 2 
CIN 3 
Total No: of cases – 45 
15 (12.5%) 
15 (12.5%) 
15 (12.5%) 
Squamous cell carcinoma  
Moderately differentiated 
Poorly differentiated 
Total No: of cases – 15 
7 (5.9%) 
8 (6.7%) 
Adenocarcinoma 
Well differentiated 
Moderately differentiated 
Poorly differentiated 
Total No: of cases – 22 
7 (5.9%) 
13 (10.9%) 
2 (1.2%) 
Reactive and benign conditions 
Squamous lesions 
Glandular lesions 
Total No: of cases – 38 
28 (23.4%) 
10 (8.3%) 
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Reactive lesions included chronic cervicitis (15 cases), regenerative atypia (2 cases), 
squamous metaplasia (2 cases), endometriosis (1 case),  granulomatous inflammation 
(1 case) and koilocytosis (6 cases), microglandular hyperplasia (6 cases), papillary 
endocervicitis (2 cases) and endocervical polyp (2 cases).  
The mean age of patients was 45.5 years with a range 18 to 70 years. The mean age of 
patients with CIN 1 was 43.3 years (Range 27 – 63 years), CIN 2 was 41.4 years (Range 
23 – 60 years), CIN 3 was 48.6 years (Range 35 – 61 years), squamous cell carcinoma 
was 52.0 years (Range 42 – 68 years) and adenocarcinoma was 50.0 years (Range 36 – 
70 years). 
54.05 % of patients with cervical carcinomas were from Tamil Nadu (54.05 %) followed 
by West Bengal (29.32 %), Andhra Pradesh (8.10 %), Jharkhand (5.4 %) and north 
eastern states (2.7 %). 
 
Figure 5: Regional distribution of cervical cancer patients   
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The most common presenting symptom was abnormal vaginal discharge (30.8 %) 
followed by cervical growth (25.0 %), abnormal uterine bleeding (21.7 %), cytological 
abnormality in Pap smear detected during routine cervical screening (15.8 %) and post 
coital bleeding (6.7 %). 
 
Figure 6: Distribution of cases according to mode of presentation. 
83.3 % of total number of patients underwent punch biopsy. The other types of biopsies 
performed were LEEP (Loop Electrosurgical Excision Procedure) and LLETZ (Large 
Loop Excision of Transformation Zone) which were restricted to CIN cases. Out of 15 
CIN 1 cases, 7 patients had under gone LEEP and 3 patients had undergone LLETZ. Out 
of 15 CIN 2 cases, 2 patients each had undergone LEEP and LLETZ and in 15 CIN 3 cases, 
1 patient and 4 patients had undergone LEEP and LLETZ respectively. 
 
31% 
25% 
21% 
16% 
7% 
Disharge PV Cervical growth Abnormal uterine bleeding
Abnormal pap smear Post coital bleeding
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Table 3: Distribution of CIN cases according to the type of biopsy. 
Diagnosis Punch biopsy LEEP LLETZ 
CIN 1 
CIN 2 
CIN 3 
5 (33.3 %) 
11 (73.3 %) 
10 (66.6 %) 
7 (46.6 %) 
2 (13.3 %) 
1 (6.6 %) 
3 (20 %) 
2 (13.3 %) 
4 (26.6 %) 
 
Koilocytic change was seen in  28 out of 120 cases. 8 cases of CIN 1 (53.3 %), 10 cases of 
CIN 2 (66.6 %) and 4 cases of CIN 3 (26.6 %) showed koilocytic change in the adjacent 
epithelium. There was a statistically significant association between koilocytic change 
and CIN 1 and CIN 2 (p value 0.03 and < 0.01 respectively) and not with CIN 3 (p value = 
0.7). However, it was observed that there was no statistically significant difference 
within each subtype of CIN and koilocytic change. 
Table 4: Association between koilocytosis and CIN  
Diagnosis Koilocytes present Koilocytes absent P value 
Reactive 
CIN 1 
CIN 2 
CIN 3 
6 (20 %) 
8 (53.3 %) 
10 (66.6 %) 
4 (26.6 %) 
24 (80 %) 
7 (46.7 %) 
5 (33.3 %) 
11 (73.3 %) 
 
0.03 
<0.01 
0.7 
 
The morphological features analysed were (1) Nuclear enlargement, hyperchromasia, 
membrane irregularity. (2) loss of polarity, (3) mitotic count. Out of these, it was 
observed that mitotic count was the only parameter which showed statistically 
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significant difference within the subtypes of CIN. (Calculated using Kruskal Wallis non 
parametric test, p value <0.001). 
Table 5: Clinical features and histological parameters in the cervical dysplastic lesions. 
 CIN 1 CIN 2 CIN 3 SCC AdC 
Mean age ( years) 
 
Commonest mode of 
presentation 
 
Koilocytic change 
 
Mean mitotic count/ 
10hpf  
43.3  
 
Abnormal 
Pap smear 
 
53.3 % 
 
4.1 
41.4 
 
Vaginal 
discharge 
 
66.6 % 
 
5.6 
48.6 
 
Vaginal 
discharge 
 
26.6 % 
 
9.4 
52.0 
 
Cervical 
growth 
 
 
 
11.4 
50.0 
 
Cervical 
growth 
 
 
 
10.5 
 
P16 expression in cervix in reactive, premalignant and malignant squamous and 
glandular lesions. 
 
Amongst the reactive lesions, 2 cases of squamous metaplasia, 2 cases of chronic 
cervicitis, 1 case of microglandular hyperplasia and 1 case of endometriosis showed 
patchy weak cytoplasmic positivity for p16. The remaining 34 cases including the 6 
cases of koilocytosis were completely negative for p16. 
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Table 6: Pattern of p16 expression in various cervical biopsy specimens 
 Total no: of 
cases positive 
for p16 
Strong  Moderate Weak 
CIN 1 11/15(73.3 %) 3/11(27.2 %) 4/11(36.3 %) 4/11(36.3 %) 
CIN 2 14/15(93.3 %) 9/14(64.2 %) 5/14 (35.7 %)  
CIN 3 14/15 (93.3 %) 14/14(100.0%)   
SCC 15/15(100.0 %) 14/15(93.3 %) 1/15(6.6 %)  
AdC 21/22(95.4 %) 18/21(85.7 %) 3/21(14.2 %)  
Reactive 6/38(15.7 %)   6/38 (15.7 %) 
 
Expression pattern of p16 in CIN 1 
 
11 out of 15 cases of CIN 1 showed nuclear positivity for p16, out of which 4 cases 
demonstrated weak staining, 4 cases moderate staining and 3 cases showed strong 
staining. 4 cases showed complete absence of p16 immunostaining. ROC curve 
(Receiver Operator Characteristic) was generated to assess the performance indicators. 
When the threshold was set at a score of 2, the sensitivity, specificity, positive predictive 
value and negative predictive were detected to be 73.3 %, 85.7 %, 73.3 % and 85.7 %. 
With the cut off set at a score of 5, the sensitivity dropped to 26.6 %. The positive 
predictive value and negative predictive value were 50.0 % and 68.5 % respectively. 
 
 
 
69 
 
Table 7: Performance indicators of p16 in CIN 1 
 Sensitivity Specificity PPV NPV 
Score 2 
Score 5 
73.3 % 
26.6 % 
85.7 % 
85.7 % 
73.3 % 
50.0 % 
85.7 % 
68.5 % 
 
 
 
 
Figure 7: ROC curve depicting p16 expression in CIN 1 
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Expression pattern of p16 in CIN 2 
 
Out of 15 cases of CIN 2, 14 cases showed positivity for p16 out of which strong and 
diffuse nuclear positivity was observed in 9 cases (64.2 %) and moderate positivity in 5 
cases (35.7%). With the cut off set at a score of 2, the sensitivity, specificity, positive 
predictive value and negative predictive value obtained were 93.3 %, 85.7 %, 77.78 % 
and 96 % and with a cut off set at a score of 5, the sensitivity, positive and negative 
predictive values were found to be 86.6 %, 85.7 %, 76.4 % and 92.3 %. 
Table 8: Performance indicators of p16 in CIN 2 
 Sensitivity Specificity PPV NPV 
Score 2 
Score 5 
93.3 % 
86.6 % 
85.7 % 
85.7 % 
77.7 % 
76.4 % 
96.0 % 
92.3 % 
 
 
 
Figure 8: ROC curve depicting p16 expression in CIN 2 
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Expression pattern of p16 in CIN 3 
 
Out of the 15 cases of CIN 3, 14 cases showed strong and diffuse nuclear positivity for 
p16 and 1 case showed complete absence of staining. With the cut off set at a score of 2, 
the sensitivity, specificity, positive predictive value and negative predictive value 
obtained were 93.3 %, 85.7 %, 77.78 % and 96 %. 
Table 9: Performance indicators of p16 in CIN 3 
 Sensitivity Specificity PPV NPV 
Score 2 
Score 5 
93.3 % 
86.6 % 
85.7 % 
85.7 % 
77.7 % 
76.4 % 
96.0 % 
92.3 % 
 
 
Figure 9: ROC curve depicting p16 expression in CIN 3 
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Expression pattern of p16 in Squamous Cell Carcinoma 
 
Out of the 15 cases of Squamous Cell Carcinoma, all 7 cases of moderately differentiated 
squamous cell carcinomas and 7 out of 8 cases of poorly differentiated carcinomas 
showed diffuse and strong staining for p16. 1 case of poorly differentiated carcinoma 
showed moderate staining.  With cut off set at a score of 2 and 5, the sensitivity, 
specificity, positive predictive value and negative predictive value observed were    
100.0 %,  85.7 %, 78.9 % and 100 .0 % respectively. 
Table 10: Performance indicators of p16 in SCC 
 Sensitivity Specificity PPV NPV 
Score 2/5 100.0% 85.7 % 78.9% 100.0% 
 
 
Figure 10: ROC curve depicting p16 expression in squamous cell carcinoma 
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Expression pattern of p16 in adenocarcinoma 
 
Out of 22 cases of adenocarcinoma, 1 case was negative, 3 cases showed moderate 
staining and 18 cases showed strong and diffuse staining for p16. ROC curve generated 
with a cut off set and a score of 2 and 5 gave a sensitivity, specificity, positive predictive 
value and negative predictive value of 95.45 %, 80.0 %, 91.3 % and 88.9 % respectively. 
Table 11: Performance indicators of p16 in Adenocarcinoma 
 Sensitivity Specificity PPV NPV 
Score 2/5 95.45% 80.0% 91.3% 88.9% 
 
 
Figure 11: ROC curve depicting p16 expression in adenocarcinoma 
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While evaluating p16 expression, between intensity and proportion, the reaction 
intensity correlated better with the severity of the lesion calculated from Bland Altman 
plot. 
 
Figure 12: Bland Altman plot comparing intensity and proportion of p16 expression 
Correlation of p16 with tumour differentiation 
 
Statistical significance for association of p16 expression and differentiation of tumour 
was assessed (using non parametric Kruskal Wallis test). A total of 37 carcinomas were 
included in the study, out of which 7 were moderately differentiated squamous cell 
carcinoma, 8 poorly differentiated squamous cell carcinoma, 7 well differentiated 
adenocarcinoma, 13 moderately differentiated adenocarcinoma and 2 poorly 
differentiated adenocarcinoma. There was no statistically significant association 
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between the differentiation of tumour and p16 expression (Kruskal Wallis non 
parametric test, p value = 0.9) 
Table 12: Correlation of p16 expression with different grades of carcinoma 
 No. Of cases P16 
expression 
P value 
Well differentiated * 
Adenocarcinoma 
 
7/7 (100.0 %) 
 
7/7 (100.0 %) 
 
 
 
 
0.9 
Moderately differentiated 
Squamous cell carcinoma 
Adenocarcinoma 
 
7/20 (35.0 %) 
13/20 (65.0 %) 
 
 
7/7 (100.0 %) 
12/13(92.3%) 
Poorly differentiated 
Squamous cell carcinoma 
Adenocarcinoma 
 
8/10 (80.0 %) 
2/10 (20.0 %) 
 
8/8 (100.0 %) 
2/2 (100.0 %) 
*There were no cases of well differentiated squamous cell carcinoma included in this 
study. 
 
Correlation of p16 overexpression with radiological parameters 
 
p16 overexpression is defined as a total score of 8. 
 
Radiological staging 
Radiological staging was available in all 37 cases of carcinomas. Non parametric Kruskal 
Wallis test was used for assessment of statistical significance. It was found that p16 
overexpression has statistically significant association with stage of the tumour.              
(p value = 0.01). 
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Lymph node metastasis 
Out of 37 cases of carcinomas, 13 cases had documented lymph node metastasis. Using 
Mann Whitney U test, it was found that there is a statistically significant association 
between p16 overexpression and lymph node metastasis. (p value = 0.01) 
Local and distant metastasis 
 
15 out of 37 cases had no local or distant metastasis. 17 cases had local metastasis to 
parametrium or vagina. 5 cases had metastasized to lung or liver. There was a 
statistically significant association between p16 expression and metastasis. (Kruskal 
Wallis test; p value = <0.01) 
Table 13: Correlation between radiological parameters and p16 expression. 
Radiological parameter 
 
 
Total No: of cases p16 
overexpression 
p value 
Radiological staging 
Stage I 
 
Stage II 
 
Stage III 
 
Stage IV 
 
14/37(38.8%) 
 
5/37(13.8%) 
 
13/37(33.3%) 
 
5/37(13.8%) 
 
 
3/14 (21.4 %) 
 
3/5 (60.0 %) 
 
13/13 (100.0 %) 
 
5/5 (100.0 %) 
 
 
 
 
0.01 
Lymph node metastasis 
Present 
 
Absent 
 
13/37(35.1%) 
 
24/37(64.8%) 
 
 
13/13 (100.0 %) 
 
11/24 (45.8 %) 
 
0.01 
Metastasis 
Absent 
 
Local metastasis 
 
Distant metastasis 
 
15/37(40.5%) 
 
17/37(45.9%) 
 
5/37(13.5%) 
 
3/15 (20.0%) 
 
16/17 (94.1%) 
 
5/5 (100.0 %) 
 
 
<0.01 
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Correlation between cervical cytology and biopsy 
 
Out of 120 cases, 74 cases had a Pap smear immediately prior to cervical biopsy. 39 
cases (52.7 %) were negative for intraepithelial lesion / malignancy, 9 cases (12.1 %) 
were diagnosed as Low grade Squamous Intraepithelial Lesion(LSIL), 15 cases (20.2 %) 
as High grade Intraepithelial Lesion(HSIL), ASC – H (Atypical Squamous Cells – cannot 
exclude HSIL) was diagnosed in 4 cases (5.4 %), Atypical Glandular Cells, favour 
neoplastic was diagnosed in 3 cases (4.05%) and 1 case was diagnosed as squamous cell 
carcinoma (1.35 %) and 3 smears (4.05 %) were unsatisfactory for evaluation. 
  
 
Figure 13: Distribution of cases according to diagnoses on Pap smear. 
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Out of all the 38 reactive conditions, 27 cases had previous Pap smear diagnosis. All the 
cases were reported as negative for intraepithelial lesion / malignancy.  
All the 15 cases of CIN 1 had previous Pap smears out of which 7 cases were reported as 
negative for intraepithelial lesion / malignancy. 5 cases were reported as LSIL, 1 case as 
ASC – H, 1 case as atypical glandular cells and 1 smear was unsatisfactory for evaluation. 
Thus, the sensitivity and specificity of cytology to detect CIN 1 was found to be 41.67% 
and 100 % respectively. The positive predictive value was 100 % and negative 
predictive value was 79.4 %. 
Out of 45 CIN 2/3/SCC cases, 27 cases had previous Pap smear, HSIL was diagnosed in 
14 cases, LSIL in 4 cases, ASC – H in 3 cases, squamous cell carcinoma in 1 case and 
negative for intraepithelial lesion in 4 cases. 1 smear was unsatisfactory for evaluation. 
Thus, the sensitivity and specificity of HSIL to detect a high grade lesion was 65.2% and 
100% respectively. The positive predictive value was 100 % and negative predictive 
value was 84 %. 
A diagnosis of ASC – H was made in 4 cases, out of which 3 cases were diagnosed as CIN 
3 on biopsy and 1 case as CIN 1. 
Out of 22 cases of adenocarcinoma, only 5 patients had undergone Pap smear test. 1 
smear was reported as negative for malignant cells, 2 cases as atypical glandular cells, 
favour neoplastic, 1 case as HSIL and 1 case as unsatisfactory for evaluation. The 
sensitivity and specificity of cytology in adenocarcinoma was found to be 66.67 % and 
specificity to be 100 %. The positive and negative predictive values were 100 % and 
87.5 % respectively. 
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Table 14. Distribution of cytology cases according to diagnoses 
 CIN 1 CIN 2/3/SCC Adenocarcinoma Reactive 
Total No. Of 
cases 
 
15/15 (100%) 
 
 
27/45(60.0 %) 
 
 
5/22 (22.7 %) 27/38(71.05%) 
LSIL 
 
5/15(33.3%) 
 
4/27 (14.8%) 
 
  
HSIL 
 
 
 
14/27(51.8%) 
 
1/5 (20.0%)  
ASC-H 
 
1/15(6.6%) 
 
3/27 (11.1 %) 
 
  
SCC 
 
 
 
1/27 (3.7 %) 
 
  
AGC, 
neoplastic 
 
1/15(6.6%) 
 
 
 
2/5 (40.0 %)  
NELM 
 
7/15(46.6%) 
 
4/27 (14.8 %) 
 
1/5 (20.0 %) 27/27(100.0%) 
Unsatisfactory 1/15(6.6%) 1/27 (3.7 %)  1/5 (20.0 %)  
 
 
Table 15: Performance indicators of cytology 
 Sensitivity Specificity PPV NPV 
LSIL 
HSIL/SCC 
Atypical 
glandular cells 
35.7% 
69.2% 
50.0 % 
92.9 % 
95.5 % 
98.5 % 
55.5 % 
90.0 % 
66.6 % 
85.4% 
84.3% 
97.0% 
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Follow up data was available in 21 out of 45 cases. The follow up period ranged from 3 
months to 36 months. Mean follow up period was 11.2 months. 
Out of 15 cases of CIN 1, follow up data was available in 10 cases. There was complete 
regression in 2 cases. There was persistence of CIN 1 in 3 cases. 3 cases and 2 cases 
progressed to CIN 2 and CIN 3 respectively. 
 Out of 15 cases of CIN 2, follow up data was available in 7 cases. Complete regression 
was observed in 2 cases, persistence of CIN 2 in 1 case and progression to CIN 3 in 4 
cases. 
 Out of 15 cases of CIN 3, 4 cases had follow up information. It was observed that 1 case 
progressed to squamous cell carcinoma and 3 cases persisted as CIN 3. 
The time( in months) taken for progression into a higher grade lesion was estimated to 
be 16 months using Kaplan Meir curve.
 
Figure 14: Kaplan Meir curve for assessment of progression into higher grade 
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Figure 15: Thin Prep smear showing reparative change(20X) 
 
 
Figure 16: Stratified squamous epithelium of ectocervix with mild reparative 
change(H&E, 20X) 
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Figure 17: Stratified squamous epithelium with mild reparative change (H&E, 10X) 
 
 
Figure 18: Absent p16 expression in reparative epithelium (10X) 
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Figure 19: Thin Prep smear showing a koilocyte (20X) 
 
 
Figure 20: Ectocervical epithelium displaying koilocytosis (H&E,20X) 
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Figure 21: Ectocervical epithelium with koilcytosis (H&E,10X) 
 
 
Figure22: Absent p16 expression in the koilocytes (10X) 
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Figure 23: Thin Prep smears showing benign endocervical glands in microglandular 
hyperplasia (20X) 
 
Figure 24: Microglandular hyperplasia (H&E,10X) 
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Figure 25: Microglandular hyperplasia(H&E,20X) 
 
 
Figure 26: Absent p16 staining in benign endocervical glands(20X) 
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Figure 27: Thin Prep showing LSIL (20X) 
 
 
Figure 28: CIN 1 (H&E,40X) 
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Figure 29: CIN 1 (10X) 
 
 
Figure 30: p16 staining the dysplastic epithelium in the lower one third (20X) 
 Inset: Nuclear staining by p16(40X). 
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Figure 31: Thin Prep demonstrating HSIL (20X) 
 
 
Figure 32: CIN 2 (H&E, 40X) 
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Figure 33: CIN 2 (10X) 
 
 
Figure 34: p16 staining the dysplastic epithelium in lower two thirds(20X) 
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Figure 35: Thin Prep demonstrating HSIL (10X) 
 
 
Figure 36: CIN 3 (H&E, 40X) 
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Figure 37: CIN 3 (H&E,20X) 
 
 
Figure 38: p16 staining the dysplastic epithelium full thickness(20X) 
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Figure 39: Thin Prep smear showing Squamous cell carcinoma(10X) 
 
 
Figure 40: Squamous cell carcinoma (H&E,40X) 
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Figure 41: Squamous Cell Carcinoma (H&E, 20X) 
 
 
Figure 42: Diffuse and strong p16 staining in Squamous Cell carcinoma(20X) 
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Figure 43: Atypical glandular cells, favour neoplastic (20X) 
 
 
Figure 44: Adenocarcinoma(H&E, 40X) 
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Figure 45: Adenocarcinoma (H&E,10X) 
 
 
Figure 46: p16 staining in adenocarcinoma(10X) 
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DISCUSSION 
 
India is a zone of high prevalence for cervical carcinomas with 20 % of new cases 
diagnosed every year(2). As cervical carcinomas evolve from distinct premalignant 
conditions, early detection and treatment plays a large role in reducing cancer related 
morbidity and mortality. Pap smear test, which is a simple and cost effective mass 
screening tool has drastically reduced the incidence of cervical cancer in developed 
countries over the past decades. As causal association of cervical neoplasia with Human 
Papilloma Virus was established, vaccines were developed thus, making it one of the 
few malignancies which are vaccine preventable.  
The role of p16 and HPV has been extensively studied over the last two decades and has 
shown to play a major role in cervical tumourigenesis(58)(64). The biomarker, p16 has 
emerged as a reliable diagnostic as well as prognostic marker in cervical intraepithelial 
lesions. High risk HPV, most commonly subtypes 16 and 18 are responsible for almost 
all cases of cervical carcinomas. However, the mere presence of HPV in the cervical 
epithelium does not imply the presence of a neoplastic lesion. It is the persistence and 
integration of viral genome into the host that causes neoplastic transformation of 
epithelial cells(21). Hence, direct HPV DNA detection, though has a high sensitivity is 
not sufficiently specific to detect CIN or carcinoma. 
 Studies have shown that overall prevalence of high risk Human Papilloma Virus in 
inflammatory, CIN grades 1, 2 and 3 and invasive cancers to be 37.6%, 63.5%, 97.2% 
and 92% respectively. The most prevalent subtype was HPV16 (19). However, it was 
necessary to establish alternate methods other than HPV DNA detection due to high cost 
and a relatively low specificity. 
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Pap smear testing is universally accepted and widely used as a screening tool to detect 
premalignant and malignant conditions of cervix. Various studies have proven that Pap 
test has variable sensitivity and sufficiently high specificity to detect cervical dysplastic 
lesions(40)(37). 
The aim of our study is to investigate the role of p16 as a surrogate marker for cervical 
dysplastic lesions and carcinoma and to evaluate the diagnostic accuracy of cervical 
cytology compared to corresponding cervical biopsy samples. A total of 120 cases were 
chosen with relatively more number of CIN cases (15 cases each of CIN 1, 2 and 3) as 
they are more diagnostically challenging than frank carcinomas. Considerable 
interobserver variation has been observed in interpreting both cytology and biopsy 
samples. Hence, an objective “gold standard” which would be HPV DNA detection should 
have been performed in all cases. But as the cost of this test would be high, we have 
chosen only the cases that have adhered strictly to the diagnostic criteria mentioned in 
Robboy’s Pathology of Female Genital Tract to ensure accurate histomorphological 
diagnosis. 
Clinical Features 
 
In this study, majority of the patients with cervical carcinoma were from Tamil Nadu 
(54.05%). The highest incidence of cervical cancer in India is reported from Tamil Nadu 
(Age adjusted Incidence rate: 30.6 per 1, 00,000 women)(10).  Among the 284 samples 
received, the incidence of squamous cell carcinoma was much higher than 
adenocarcinoma which is in concordance with the world demographics (85 % 
prevalence for squamous cell carcinoma compared to 15 %) for adenocarcinoma(90).  
The mean age of women with squamous cell carcinoma and adenocarcinoma was found 
to be 52.0 years and 50.0 years respectively. Studies from Western literature observe 
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two peaks at 30-34 years and 80-84 years(90). The mean age of women with CIN 1, CIN 
2 and CIN 3 were found to be 43.3 years, 41.4 years and 48.6 years respectively. A study 
done in United States (Kaiser Permanente health plan) observed highest rates of LSIL 
between 15 to 19 years of age and HSIL between 25 to 29 years of age(11) whereas; a 
study from India revealed mean age of LSIL as 32.3 years and HSIL as 40.5 years(33). 
This difference in the mean age of diagnosis could be due to the fact that more number 
of young women undergo routine cervical screening in developed countries thus 
enabling earlier detection of dysplastic lesion.  
In the present study, the most common presenting symptom was vaginal discharge 
similar to the study done by Bal et al(33). Cervical growth was the most common 
presenting symptom in women with carcinoma. However, it is encouraging to note that 
15.8 % of our patients had undergone cervical biopsy following routine Pap smear 
examination which detected cervical cytological abnormality thus implying that there is 
increasing awareness and access to screening programmes for women in our study 
cohort.  
42.2 % of the patients had undergone LEEP/LLETZ procedures. Many of the patients 
with carcinoma presented with advanced stage of disease (Stages III and IV: 47.1% as 
against 38.8 % in Stage I and 13.8 % in Stage II). 35.1 % of them had nodal metastasis. 
45.9% and 13.5% had pelvic and distant metastasis at the time of presentation 
respectively. This is in concordance with another Western study which states that stage 
of presentation is high in spite of effective screening programme(6). 
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Morphological features 
 
Out of all the morphological features assessed (Nuclear hyperchromasia, enlargement, 
membrane irregularity, loss of polarity, mitotic count); it was observed that mitotic 
count was the only feature which showed statistically significant difference within the 
subtypes of CIN. A study done on cytological samples had shown the degree of nuclear 
membrane irregularity as the most significant differentiating feature(43).  A study done 
by Aoyama et al on cervical biopsies states that is advisable to take into account all the 
morphological features before diagnosing cervical dysplastic lesions(44).  We suggest 
that combination of all histological features with emphasis on mitotic count should be 
done to make a diagnosis of cervical dysplasia. 
Immunohistochemical staining pattern of p16 
 
In our study, we found that the sensitivity of p16 to detect intraepithelial lesions 
increase with increasing severity of the lesion (73.3% to 100% from CIN 1 to Squamous 
Cell Carcinoma). . Endocervical adenocarcinoma also showed a sensitivity of 95.4 % for 
p16 expression. The specificity of p16 to detect dysplasia was also sufficiently high 
(85.7 %). The positive predictive value ranged from 73.3 % to 78.9 % (CIN 1 to SCC) and 
was as high as 91.3 % in adenocarcinoma. The negative predictive values were 85.7 %, 
100.0 % and 88.9 % in CIN,  SCC and adenocarcinoma respectively. This is in keeping 
with the data available from similar cohorts worldwide(3)(62)(26).  The study done in 
PGI, Chandigarh had got considerably lower sensitivity of p16 for CIN 1 (20%) but the 
findings were similar in high grade lesions (90% sensitive for squamous cell 
carcinoma)(71). The other Indian studies have similar expression profile(72)(73).  
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Table 16: Comparison of sensitivity of p16 obtained in other similar studies 
 Present study Lesnikova et al Mood et al Gupta et al 
CIN 1 
CIN 2 
CIN 3 
SCC 
Adenocarcinoma 
73.3 % 
93.3 % 
93.3 % 
100.0 % 
95.4 % 
72.3 % 
91.0 % 
98.3 % 
98.5 % 
81.8 % 
91.0 % 
90.0 % 
90.0 % 
75.0 % 
20.0 % 
45.0 % 
55.0 % 
95.0 % 
 
p16 has been proven to have a very high discriminatory ability to distinguish between 
normal or reactive epithelium with dysplastic epithelium. Our study showed patchy 
weak membranous and cytoplasmic positivity in 6 reactive cases. A few other studies 
have observed this aberrant expression pattern as well(58)(62)(64). This is thought to 
be due to the presence of concomitant low grade HPV that produce cytological 
abnormalities too subtle to be detected on H&E sections.  Moreover, none of the cases 
showed strong nuclear positivity.  
Table 17: Comparison of proportion of normal cases with aberrant p16 expression in 
other similar studies 
 Present 
study 
Murphy et al Tsoumpu et al Mood et al 
Normal / reactive 
cases with p16 
expression 
15.7 % 10.0 % 12.0 % 10.0 % 
 
One case of moderately differentiated adenocarcinoma and 1 case of CIN 3 showed lack 
of staining and 1 case of poorly differentiated squamous cell carcinoma showed 
moderate staining for p16. This is due to differential expression of cell cycle regulator 
genes in HPV positive and HPV negative carcinomas. Studies have shown that HPV 
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positive cancers up regulate p16, cyclin E and cyclin B and down regulate cyclin D1 due 
negative feedback inhibition of Retinoblastoma activity as a result of E7 interaction. 
HPV negative cancers show reverse pattern of p16 and cyclin D1 expression. Reduced 
expression of p16 in HPV negative cancers are thought to be due to promoter 
hypermethylation and elevated cyclin D1 expresssion due to gene amplification(77). 
 It has been consistently observed in all the studies that low grade lesions have a 
reduced expression of p16. This can be explained by the fact that many of the low grade 
lesions are associated with low grade HPV in which E7 has a reduced affinity for Rb 
protein and failure of E6 to interact with p53(27). Low risk HPV are thought to interfere 
with Notch signalling pathway. 
A diagnosis of frank carcinoma can be made even without an immunohistochemical 
marker. However, distinction of low grade intraepithelial lesion from marked 
regenerative or reparative change is diagnostically challenging usually requiring an 
immunohistochemical marker. The sensitivity of p16 to detect CIN 1 was found to be 
73.3 % and 46.6 % with a score of 2 and 5 respectively. It is comparable to the results 
obtained in most of the other similar studies. CIN 1 and many cases of CIN 2 develop in 
latently infected epithelial cells caused by multiple subtypes of HPV. High grade lesions 
are usually associated with a single high risk subtype, usually HPV 16 which causes 
abortive infection in the epithelial cell and dysregulation of viral genome with higher 
number of E7 copies produced and thus promoting E7-Rb protein interaction. 
Our study found a significant association between koilocytes and CIN 1 and CIN 2 but 
not with CIN 3. This is in keeping with other similar studies. Koilocytic atypia cannot be 
reliably distinguished with CIN 1 in many cases on H&E sections alone. It is 
controversial whether the presence of koilocytosis alone carries the adverse risk of 
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CIN1. It is therefore, essential to distinguish between the two lesions. All cases of 
koilocytosis were negative for p16 in the present study. Therefore, we propose that p16 
can be used as a reliable marker to distinguish between CIN 1 and koilocytosis.  
It was observed in this study that a small proportion of cases (6 out of 38) showed a 
patchy weak cytoplasmic / membranous positivity for p16 and another small 
proportion of neoplastic cells (1 case each of adenocarcinoma and CIN 3) showed 
absent staining. So we tried to evaluate the reliability of p16 in terms of intensity and 
proportion of expression. It was found that intensity was a better indicator of severity of 
lesion than proportion, in tune with another study which obtained similar results(3). 
Thus, a focal but strong and crisp expression is a more reliable indicator of the severity 
of lesion than a weak and patchy expression. 
The prognostic significance of tumour grade is well known. Patients with well 
differentiated tumours are known to have a better overall survival than the patients 
with poorly differentiated tumour. We observed no statistically significant difference in 
the expression patterns of p16 in well, moderately or poorly differentiated tumours. (P 
value = 0.9). However, we got a statistically significant association between p16 
expression and tumour stage, nodal status and metastasis. Tumours which over 
expressed p16 was associated with a more advance stage, positive lymph nodes and 
presence of metastasis (P value = 0.01, 0.01 and <0.01). The findings are consistent with 
a study done by Huang et al(6). As p16 is more strongly expressed in high grade lesions 
compared to low grade lesions, it is suggested that p16 may be involved in progression 
of lesion. More studies are required to elucidate the exact molecular mechanism. 
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Table 18: Comparison of prognostic value of p16 over expression with a similar study 
 Present study Huang et al 
p16 over expression 
correlated with 
Stage of tumour, lymph 
node metastasis, pelvic 
and distant metastasis 
Stage of tumour, lymph 
node metastasis, pelvic and 
distant metastasis, 
histological subtype,  
overall survival 
p16 over expression did not 
correlate with 
Grade of tumour Grade of tumour, 
lymphovascular invasion, 
parametrial and vaginal 
invasion, size and depth of 
tumour. 
 
The cause for drastic reduction in the incidence of cervical carcinomas in developed 
countries has been attributed to effective implementation of screening programmes. A 
number of studies have been done both at national and international levels to assess the 
efficacy of cervical cytology screening programme. 15.8 % of patients with 
intraepithelial lesion were referred for biopsy due to abnormal cytology detected in Pap 
smears. 
Our study showed LSIL (12 %,) HSIL (22 %) ASC H (5%), SCC (1%) and AGC (4%).  The 
rate of ASC H was slightly higher compared to another similar Indian study done by Bal 
et al(33). The overall sensitivity of cytology was 58.9 % and specificity was 90 %. This is 
comparable to the data provided by national and international studies which showed a 
sensitivity ranging from 45% to 60 % and specificity 75 % to 90 %(29)(39)(35). We 
suggest that repeat evaluation of all cytology specimens by at least two cytopathologists 
can improve the sensitivity of Pap smears in detecting dysplasia. Other modalities 
which are coming up are image analysers and chemiluminescent speculoscopy. 
Thus, in our institution the Pap testing has a sensitivity and specificity comparable to 
worldwide statistics.  
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Table 19: Comparison of sensitivity and specificity of Pap smears with other similar 
studies worldwide 
 Present 
study (high 
grade 
lesions) 
Nguyen et al Denny et al American 
Family 
Physician 
Schechter et 
al 
Renshaw et 
al 
Sensitivity 
Specificity 
69.2 % 
95.5 % 
85% 
90-99% 
44-78% 
91-96% 
55.4% 
94.1% 
84.4% 
80.0% 
50-75% 
 
 
Table 20: Comparison of sensitivity and specificity of Pap smears with other similar 
studies in Asia 
 Present study Ansari et al 
(India) 
Deodhar et al 
(India) 
Moy et al 
(China) 
Sensitivity 
 
Specificity 
69.2 % 
 
95.5 % 
70-80 % 67.7 % 
 
95.4 % 
80.2 % 
 
93.3 % 
 
It is well known that asymptomatic HPV infection is highly prevalent in sexually active 
women. However, only a small proportion of them develop an intraepithelial lesion.  
60 % of LSIL and 30 % of HSIL are thought to regress, 30 % and 60 % of LSIL and HSIL 
persist and 10 % progress to a higher grade lesion within 2 years of initial 
diagnosis(27). Our study showed that 47.6 % of patients progressed to a high grade 
lesion, 33.3% persisted and 19.0 % of lesions regressed to a lower grade lesion. The 
follow up period ranged from 3 months to 36 months with a mean follow up of 11.2 
months. The time taken for progression to a higher grade lesion was 16 months (Kaplan 
Meir curve). This warrants a close follow up of patients with Pap screening at least once 
a year in women with cervical epithelial abnormality.  
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Limitations of the study: 
(1)  The gold standard taken was cervical biopsy which is subject to interobserver 
variation. However, the slides were reviewed by two pathologists to reduce this.  
(2) The diagnosis was not confirmed with HPV DNA detection by PCR due to financial 
constraints. We plan to obtain further funding to compare our results with PCR. 
(3) Staining heterogeneity was noted, especially in cases of CIN 1. The intensity of 
staining varied within cases. This could be due to technical factors. Most of the test 
results with discrepancy were repeated to confirm. 
(4) The sample size was small for a disease with high prevalence, again due to financial 
constraints. 
(5) Clinical and follow up data were not available on all patients as this was a 
retrospective study and some of the patients were lost to follow up. 
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Recommendations 
 
This study has accomplished the aims and most of the objectives that it targeted to 
achieve. However, there is a scope for further work in this field that can lead to early 
detection and treatment of cervical cancers thereby reducing the mortality rates. 
Panel of markers: 
Various studies have proved that use of a panel of markers considerably improves the 
sensitivity and specificity of diagnosis. The recommended panel would be p16, MIB-1, 
and cyclin D. 
Distinction from endometrial adenocarcinoma: 
As adenocarcinoma can arise from endometrium as well as cervical glandular 
epithelium, it is difficult to ascertain the origin of tumour morphologically. As p16 
expression is HPV mediated and association of HPV with endocervical adenocarcinoma 
has been proven, p16 can be used to distinguish endometrial carcinoma from 
endocervical carcinoma. More studies are required in this field. 
Incorporation of HPV DNA testing: 
Since HPV DNA testing is considered the “gold standard”, all women with cervical 
cytological abnormality should undergo HPV DNA testing to subtype into high risk and 
low risk categories, as women harbouring high risk HPV are more likely to progress into 
a higher grade lesion. The knowledge of prevalence of HPV infection will also enable the 
implementation of HPV vaccination strategy more effectively. 
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Genetic profiling of cervical tumours. 
A better understanding of molecular basis of cervical tumours will help in diagnosis and 
prognostication. More studies are required in this field to predict the lesions that would 
undergo regression or progression into a higher grade. 
Maintenance of hospital based registry to document the prevalence of 
premalignant and malignant lesions of cervix 
As many of the high grade lesions are known to progress into an invasive carcinoma, 
women with cervical cytological abnormalities should be kept on close follow up. It is 
also important to know the prevalence and incidence of cervical carcinoma to 
implement effective vaccination strategy. Women should also be educated regarding the 
need for surveillance so that the number of patients lost to follow up can be reduced. 
Improving the sensitivity of Pap smear testing 
Pap smear test is still considered the most efficient screening tool in less developed 
countries. Active surveillance is required to detect early dysplastic lesions.  We 
recommend that all cytology smears should be reviewed by two cytopathologists so as 
to increase the sensitivity of Pap smears. 
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CONCLUSION 
 
 The sensitivity of p16 was 73.3 % in CIN 1, 93.3 % in CIN 2/3 and 100.0 % in 
squamous cell carcinoma. The sensitivity of p16 to detect endocervical 
adenocarcinoma was 95.4 %.  
 The protein p16 is a reliable diagnostic marker to distinguish between various 
grades of dysplasia and malignancy. 
 p16 can effectively distinguish benign mimics from dysplastic cervical lesions. 
 Intensity of p16 expression correlated with severity of the lesion better than the 
proportion of staining. 
 Over expression of p16 was associated with higher stage, nodal metastasis, 
pelvic and distant metastasis. p16 expression did not correlate with grade of 
tumour. 
 Pap test had a low sensitivity to detect low grade lesions (35.7 %) whereas the 
sensitivity for high grade lesions was sufficiently high (69.2 %). 
 Koilocytosis was significantly associated with CIN 1 and CIN 2 and not with CIN 3 
lesions. 
 Among the morphological features assessed to diagnose cervical dysplasia, 
mitotic count was the only parameter which showed significant difference 
among the subtypes of CIN and carcinoma. 
 Most common presenting symptom in women with cervical dysplasia was 
vaginal discharge and women with carcinoma presented with cervical growth.  
 47.1 % of women with carcinoma presented with advanced stage (Stage III & IV). 
 The time taken for progression of lesion to a higher grade was 16 months. 
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The results obtained in our study are in keeping with other studies conducted 
worldwide. We suggest that p16 immunohistochemical marker should be incorporated 
into routine cervical histopathological examination to improve the detection rate of 
premalignant lesions thus, enabling early detection and prevention of cervical 
carcinoma. However, more studies are required to unfold the molecular mechanisms of 
cervical carcinogenesis. The sensitivity of cervical cytology can be increased by 
concomitant use of p16 IHC at least in ambiguous cases. Thus, morphological, clinical 
and immunohistochemical parameters should be taken into account while diagnosing 
cervical dysplasia. Pap smear test as a screening modality would be reasonably effective 
as 15.8 % of asymptomatic women were detected to have cytological abnormality in our 
study. We also recommend that women with epithelial abnormality should undergo 
regular follow up at least once a year to prevent progression into higher grade lesions. 
 APPEENDIX 1
 
 
 APPENDIX 2 
Cervical dysplasias and carcinomas – A histomorphological and immunohistochemical 
study 
PROFORMA 
Serial No:    Hospital No:      Biopsy No: 
Name:           Age:   
   
Clinical: 
Mode of presentation:  
Cervical cytology: 
Radiological findings, if any: 
Type of biopsy: 
Gross: 
Micro:  
Nuclear abnormalities:  
1) Increased nuclear cytoplasmic ratio:                                        Present  [  ]            Absent [  ] 
2) Hyperchromasia:                                                                Present  [  ]            Absent [  ]             
3) Nuclear pleomorphism:                                                               Present  [  ]            Absent [  ] 
 4) Wrinkling of nuclear membrane:                                              Present  [  ]            Absent [  ]  
Mitotic activity: 
 1) Number of mitotic figures per10 high power fields:  
 2) Abnormal configurations:           Present  [  ]            Absent [  ] 
3) Loss of polarity in the epithelium: 
     Nil  [  ]              Basal one third   [  ]                      Basal two thirds [  ]      Full thickness [  ] 
Inflammatory infiltrate:                                   Conspicuous [  ]                       Inconspicuous [  ]        
Viral koilocytic change:    Present          [  ]                       Absent              [  ] 
                                         
  
Glandular lesions:   
1) Intracellular mucin:       Present  [  ]     Absent  [  ] 
2) Increased nuclear cytoplasmic ratio:      Present  [  ]     Absent  [  ] 
3) Hyperchromasia:                                                        Present  [  ]                   Absent  [  ] 
4) Nuclear pleomorphism:                                            Present  [  ]                   Absent  [  ]  
In case of carcinoma: 
Extent of invasion, if present:     <3mm  [  ]                     >3mm  [  ]                                                                                                                            
Solid areas,   if present (in case of glandular lesions):  
<5%     [  ]              5-50%   [  ]              >50%  [  ] 
Adjacent cervical tissue -    Dysplasia                         Present  [  ]                    Absent  [  ] 
 
Lymphovascular invasion:                                            Present  [  ]                     Absent  [  ] 
  Impression: 
Category:  
 
 
IHC:: Intensity (0/1+/2+/3+) Proportion(0-10%, 10-25% 25-75% and 76-100%)  and pattern 
(C/M/N) 
Antibody Tumour focus Adjacent Cervical Tissue Control 
P 16 Intensity Proportion Pattern   
      
 
Other immunohistochemical markers done:  
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